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1. Abstract 
Pulmonary fibrosis is characterized by a dysregulated wound healing response 
accompanied by the pathological replacement of functional tissue by connective tissue. 
This process leads to the malfunction of the lung and therefore mortality is considerably 
high. Suitable treatment options are scarce and the development of new therapies is 
needed.  
Increasing evidence of the contribution of innate immunity in pulmonary fibrosis 
awakened our interest in the impact of myeloid phosphatase and tensin homolog deleted 
in chromosome ten (PTEN) in this disease. The bleomycin induced pulmonary fibrosis 
model showed that myeloid PTEN deficient mice developed more severe disease 
progression than their wild-type littermates. One of the identified differences was the 
increase in IL-4, a potent inducer of alternative activation of macrophages, in the 
conditional PTEN knockout mice. Therefore we wanted to elucidate possible changes in 
the alternatively activated phenotype of macrophages and possible pro-fibrotic 
consequences. PTEN deficiency led to an elevated expression of Arginase 1 and FIZZ, 
while YM1 and MRC1 were decreased after stimulation with IL-4 or IL-13. Additionally 
Arginase 1, an important enzyme for collagen synthesis, was induced by bleomycin and 
increased in myeloid PTEN knockout mice. Thus we assume that the phosphoinositide 3-
kinase (PI3K), which action is inhibited by PTEN, is a putative mediator of alternative 
activation of macrophages and consequently exhibit a negative influence on pulmonary 
fibrosis. 
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2. Zusammenfassung 
Unkontrollierter Wundheilungsprozess in der Lunge kann zu pulmonaler Fibrose 
führen. Dabei kommt es zu einer pathologischen Vermehrung des Bindegewebes, 
wodurch es zur geminderten Lungenfunktion kommt und im Extremfall zum Tod führen 
kann. Auf Grund des Mangels an adequaten Behandlungsmethoden, besteht die 
Notwendigkeit, den Mechanismus genauer aufzuklären. Die enorme Bedeutung des 
angeborenen Immunsystems an fibrotischer Pathogenese weckte unser Interesse, mehr 
über die Funktion der myeloid expremierten Phosphatase PTEN (Phosphatase and 
Tensin homolog) zu wissen. Durch Bleomycin induzierte Lungenfibrose konnten wir 
zeigen, dass der myeloide Knockout von pten in Mäusen zu einer schwereren Fibrose 
führte, im Vergleich zu Wildtypmäusen. Zusätzlich stellten wir eine erhöhte Expression 
von IL-4 fest, welches ein wichtiges Zytokin für die Differenzierung zu alternativ aktivierten 
Makrophagen darstellt. Die Rolle von PTEN in der Differenzierung zu alternativ aktivierten 
Makrophagen, wurde durch die Stimulierung von alveolären Makrophagen mit IL-4 und 
IL-13 getestet. Der Mangel an PTEN bewirkte eine erhöhte Expression von Arginase 1 
und FIZZ, während YM1 und MRC1 in geringem Ausmaß gebildet wurden. Um deren 
Relevanz für Bleomycin induzierte Lungenfibrose zu deklarieren, wurde die Expression 
von Arginase 1 während der Krankheit untersucht. Dabei wurde entdeckt, dass deren 
Expression durch Bleomycin induziert wurde und in den myeloiden PTEN knockout 
Mäusen erhöht war. Dass lässt den Schluss zu, dass die Phosphoinositol 3-kinase (PI3K), 
welche durch PTEN inhibiert wird, die alternative Aktivierung von Makrophagen, sowie die 
Fibrogenese beeinflusst. 
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3. Abbreviations 
Akt  Protein kinase B (PKB) 
AP1  Activator protein 1 
Arg1  Arginase 1 
BLM   Bleomycin 
C57BL/6J  C57 Black 6 mice from the Jackson Laboratory 
CCL  Chemokine (C-C motif) ligand 
CD  Cluster of differentiation 
CpG ODN  Cytpsine phosphodiester guanine oligodoxynucleotides 
Cre  Cyclization recombination 
CXCL  Chemokine (C-X-C motif) ligand 
DCs  Dendritic cells  
DNA  Deoxyribonucleic Acid 
dNTPs  Deoxyribonucleotide Triphosphate 
ECM  Extracellular matrix 
EGF   Epithelial growth 
ELISA  Enzyme-linked Immunosorbent Assay 
FcγR   Fragment , crystalline receptor for immunoglobulin G 
Foxp3   Forkhead box P3 
FR   Folate receptor 
GR   Galactose receptor 
GSK-3β  Glycogen synthase kinase 3β 
H&E staining  Hematoxylin and eosin staining 
H3K27   Histon 3 Lysine 27 
H3K4   Histon 3 Lysine 4 
i.n.  Intranasal 
i.p.  Intraperitoneal 
i.t.  Intratracheal 
i.v.  Intravenaous  
Ig   Immune globulin 
IL  Interleukin 
INF-γ  Interferon γ  
iNOS  Inducible nitric-oxide synthase (NOS2) 
IPF  Idiopathic pulmonary fibrosis 
IRF4  Interferon regulatory factor 4  
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JMJD3   Jumonji domain containing 3 
LAP  Latency- associated protein 
LPS  Lipopolysaccharide 
LysM  Lysozym M 
M1  Phenotype of classically activated macrophages 
M2  Phenotype of alternatively activated macrophages 
MCP-1  Monocyte chemoattractant protein 1 (CCL2) 
MDSCs   Myeloid derived suppressor cells  
MHCII  Major Histocompatibility Complex II  
MIP-1 α   Macrophage inflammatory protein 1α (CCL3)  
MMP   Matrix metalloprotease 
MR   Mannose receptor 
NFAT  Nuclear factor of activated T-cells 
NF-κB  Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NO  Nitric oxide 
NOS  Nitric oxid synthase 
OAT   Ornithine amino transferase 
ODC  Ornithine decarboxylase 
PAMPs   Pathogen- associated molecular patterns 
PCR  Polymerase Chain Reaction 
PDGF   Platelet derived growth factor 
PDK  Phosphoinositde- dependent kinase 
PI3K  Phosphoinositde 3-kinase 
PPAR-γ  Peroxisome proliferator-activated receptor 
PPR  Pattern recognition receptor 
PtdIns  Phosphatidylinositols 
PtdIns (4)P   Phosphatidylinositol 4-phosphate 
PtdIns (4,5)P2   Phosphatidylinositol 4,5-bisphosphate (PIP2) 
PtdIns(3,4,5)P3   Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
PTEN  Phosphatase and tensin homolog deleted on chromosome 10 
qPCR  Quantitative Real Time Polymerase Chain Reaction 
RNA  Ribonucleic Acid 
RORγt  Orphan Nuclear Receptor 
ROS  Reactive oxygen species 
RT  Room temperature 
SAC   Staphylococcus aureus Cowan’s antigen 
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SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamid Gel electrophoresis 
SHIP  SH2 domain- containing inositol phosphatase 
SR   Scavenging receptor 
STAT6  Signal transducer and activator of transcription 
Syk  Spleen tyrosine kinase 
TAM   Tumor associated macrophage 
TCR   T-cell receptor 
Tfh cell  T follicular helper cell 
TH1-Cells  T helper cell type 1 
TH2-Cells  T helper cell type 2 
TLR  Toll Like Receptor 
TNF  Tumor necrosis factor 
TRAF6  TNF receptor associated factors 6 
TREG-Cells  Regulatory T cells 
TSLP  Thymic stromal lymphopoietin 
VEGF  Vascular endothelial growth factor 
α-SMA  Alpha smooth muscle actin 
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4.  Introduction 
4.1. Immune System 
The immune system comprises all molecules, proteins, cells and tissues, which are 
involved in host defense and healing. Furthermore it has to recognize invaders and to 
distinguish between host and pathogens in order to spare the host and to eliminate the 
pathogen. The mammalian immune system can be divided into to two arms: the innate 
and the adaptive immunity (Beutler 2004).  
4.1.1. Innate Immune System 
The first challenge that pathogens have to meet and to overcome is the barrier 
provided by epithelial cells or the mucus in the gastrointestinal, respiratory and 
genitourinary tract, produced by the epithelium. If pathogens succeed in breaking through 
these initial barriers, the innate immune system has additional defense mechanisms 
composed of cellular and humoral components. The cells – neutrophils, basophils, 
eosinophils, mast cells, macrophages, monocytes and dendritic cells – participating in the 
innate immune response derive from the hematopoietic stem cell through the myeloid arm 
(Chaplin 2003).  
Neutrophils are important for bacterial clearance because they phagocyte bacteria 
and produce reactive oxygen species (ROS) to kill them. In addition they generate 
cytokines such as tumor necrosis factor (TNF) and interleukin 12 (IL-12) and thereby 
contribute to tissue remodeling and repair (Chaplin 2003). 
In the blood stream circulating monocytes will differentiate into macrophages, if they 
enter a tissue. There they are important in phagocytosis of microbes and bacterial and 
viral moieties opsonized with antibodies or factors of the complement system (described 
below). They eliminate the pathogens via nitric oxide (NO) and stimulate T-cell response 
via the production of cytokines as will be further explained below. Macrophages can 
present antigens of pathogens to T helper cells via class I and class II major 
histocompatibility complex (MHC) molecules, in addition to dendritic cells, which are more 
skilled in antigen presentation (Chaplin 2003). 
Eosinophils and basophils produce cytokines and influence the inflammatory 
environment. They are mainly involved in the defense against parasites – such as 
helminthes – and in allergic reactions eosinophils and mast cells (Beutler 2004). 
Introduction 
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The innate immune cells sense pathogens with a limited number of germline 
encoded receptors (Chaplin 2003). These receptors are called pattern recognition 
receptors (PRRs). Examples are the Toll-like receptors (TLRs) that can bind pathogen-
associated microbial patterns (PAMPs). PAMPS are molecular moieties, which are 
characteristic for related groups of microbes. More precisely PRRs bind specific 
molecules instead of patterns (Beutler 2004). The great advantages of the PAMPs are 
that a related group of microorganisms express the same PAMPs, which are absent in the 
host. Moreover these molecules are crucial for the microbial survival, thus microbes 
require them. In this respect PAMPs are great weak points for the innate immune system 
to target lots of various microorganisms with the appropriate PRRs (Medzhitov 2007). In 
this way the innate immune system is able to react immediately on pathogens. In humans 
ten TLRs are known and in mice eleven. After sensing the pathogen the immune cells 
produce reactive nitrogen intermediates (RNI) and reactive oxygen species (ROS), for 
instance superoxid (O2) and hydrogen peroxide (H2O2) within the phagosome to eliminate 
invaders (Beutler 2004; Biswas and Mantovani 2010). 
Soluble proteins and bioactive molecules support the innate immune cells. These 
humoral factors are either permanently present in the blood flow or are released by the 
immune cells during an immune response (Chaplin 2003). Members of the protein family 
the collectins – for example mannose-binding protein – and the pentraxin – for instance C-
reactive protein – bind microbes via a mannosyl residue or supposable lectin-like 
interactions, respectively (Beutler 2004). Binding of the mannose-binding protein induces 
the activation of the complement system. The complement system comprises serum and 
cell surface proteins, which undergo a cascade of proteolytic cleavage of zymogens after 
activation. Three routes of activation are known: the classical pathway, the mannose 
binding lectin pathway and the alternative pathway, which are triggered by antigen- 
antibody complexes, mannan- containing microbes and microbial components, 
respectively. The complement activation can lead to mast cell degranulation, edema and 
the recruitment of immune cells; moreover microbes can be killed via the complement 
membrane attack complex that induces cell lysis (Chaplin 2003).  
Additional humoral factors are antimicrobial peptides. There are two main families in 
mammals: the defensins expressed by neutrophils and the cathelicidins produced by the 
epithelium. These peptides can breakup bacterial membranes by an unknown mechanism 
(Beutler 2004). 
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4.1.2. Adaptive Immune System 
The adaptive immunity is maintained mainly by conventional T- and B- lymphocytes 
and gets activated by the antigen presentation of innate immune cells. In contrast to the 
cells of innate immune system, cells of the adaptive immunity adjust their T-cell receptor 
or B-cell receptor diversity according to the pathogen. Somatic recombination of variable 
and constant gene fragments, insertion of non-templated nucleotides and gene 
conversion lead to the establishment of a great variety of completely new assembled 
receptor. The B-cell receptor can be additionally modified by somatic hypermutations 
(Medzhitov 2007).  
Lymph nodes and spleen drain most of the body’s tissue fluids and the blood, 
respectively and lymphocytes move among the lymph nodes. Antigen-presenting cells – 
such as dendritic cells – of the innate immune system migrate into the lymph node once 
they processed an antigen. In the lymph node they present their antigen towards 
conventional lymphocytes, which are specific for this antigen. The presentation leads to 
the differentiation of the lymphocyte into an effector cell dependent on the antigen. 
Cytokines and chemokines instruct the lymphocyte about their differentiation and the site 
of infection, respectively (Medzhitov 2007). Thus the lymphocyte with the best adapted 
receptor or immunoglobulin has to proliferate to provide enough effector cells and 
antibodies. Therefore the adaptive immune response begins after the innate immune cells 
have reacted (Chaplin 2003). After the initiation of the T-cell response and the clonal 
expansion, the contraction phase is triggered. This phase is characterized by the 
apoptosis of effector T-cells to regain homeostasis. Only a small subpopulation survives 
and forms memory T-cells with an extended life span. The persistence of a low level of 
memory T-cells is maintained by constant T-cell proliferation and apoptosis. It is believed 
that MHC and T-cell receptor (TCR) interaction as well as IL-15 and IL-17 are required for 
this homeostasis (Schluns and Lefrancois 2003). In addition to the memory T-cell memory 
B-Cells are developed. The great advantage of memory cells provide is that the host can 
induce more rapid and more specific immune responses against the same microbe at 
second infection (Chaplin 2003). 
Conventional T-cells (αβ T cells) most derive from the hematopoietic stem cell and 
differentiate in the thymus to mature T lymphocytes. Different types of effector T- cells can 
be identified such as T helper cells (discussed later). Cytotoxic T-cells are capable to 
identify infected host cells – for example by a virus – via the major histocompatibility 
complex class I (MHCI). Recognized infected host cells are eliminated by cytotoxic T-
cells, while healthy host cells are spared. This process is known as self-tolerance. The T 
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helper cells recognize pathogens via MHC II and are required for the maturation of B- 
cells and induce class switching and somatic mutations through cytokines (Chaplin 2003).  
Conventional B-cells (B2 cells) originate from the hematopoietic stem cell and 
mature in the bone marrow, in contrast to T-cells. B-cells can differentiate to plasma cells 
and produce antibodies, which are the humoral part of the adaptive immune system 
(Chaplin 2003). Activation of B-cells is mediated by the binding of unprocessed antigen to 
the B-cell receptor, which is assembled of immunoglobulin heavy and light chains 
(Harwood and Batista 2008). 
In addition to the conventional T- and B- lymphocytes innate-like lymphocytes 
support the adaptive immune system. B1 cells, marginal-zone B cells, natural-killer T cells 
and parts of γδ T cells are examples. They vary from the conventional cells in their 
receptor, which is assembled in a similar way, but less randomly and limited (Medzhitov 
2007). 
 
4.1.3. Cytokines and Chemokines 
Cytokines are secreted proteins, which are released during an inflammatory 
response by various immune, epithelial and endothelial cells. They serve as 
communication tools between the respective cells and are very important for modulating 
the innate and adaptive immune response (Krishnamoorthy and Honn 2006). They 
function via binding to cell surface receptors and induce intracellular signal transduction 
(Chaplin 2003). An essential part of the cytokines responsible for immune reaction is the 
chemokine family. Chemokines bind to receptors of the seven transmembrane G-protein 
coupled receptor family and recruit inflammatory cells – such as neutrophils – via 
chemotaxis to the site of infection. They participate mainly in mediating inflammation, 
angiogenesis and homeostasis. (Krishnamoorthy and Honn 2006) 
 
4.1.4. Phosphoinositide 3-kinase Pathway 
The phosphoinositide 3-kinases (PI3K) are conserved signal transducing 
heterodimeric enzymes composed of a catalytic and a regulatory subunit. According to 
their structure PI3Ks can be divided into the three classes I, II and III. This thesis will only 
focus on the class I PI3K, which consists of one of the catalytic subunits p110α, p110β or 
p110δ and one of the regulatory subunits p85α, p85β or p55γ (Domin and Waterfield 
1997). 
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The PI3K pathway plays a major role in the regulation of growth, proliferation, 
survival and migration of cells. Growth factors, inflammatory components, hormones, 
antibodies and antigens can induce the activation of the PI3K pathway (Marone, 
Cmiljanovic et al. 2008). In resting cells the activity of the PI3K is suppressed by the 
catalytic subunit. Activation of the PI3K through growth factors is triggered by the direct 
contact of the regulatory subunit with the phosphotyrosine residues of the growth factor 
receptors or its adaptor proteins. This event leads to the translocation of the PI3K toward 
the plasma membrane in close proximity to its substrates (Cantley 2002). The activated 
PI3K phosphorylates the 3-hydroxyl group of phosphatidylinositols (PtdIns), PtdIns (4)P 
and PtdIns (4,5)P2 (PIP2), whereby PIP2 is the preferred substrate in vivo (see Figure 1) 
(Vanhaesebroeck, Leevers et al. 2001). Phosphorylation of PIP2 generates 
PtdIns(3,4,5)P3 (PIP3), which induces the translocation of the serine-threonine kinase 
protein kinase B (PKB, Akt) toward the plasma membrane. This kinase is recruited to the 
plasma membrane through its pleckstrin- homology (PH)- domains, which bind the PIP3 
(Marone, Cmiljanovic et al. 2008). PH- domains of different proteins are able to distinguish 
between PtdIns(3,4)P2, PtdIns(3,4,5)P3 and other lipids and thus provide the specificity of 
the PI3K pathway (Fruman and Cantley 2002). At the plasma membrane different kinases 
can activate Akt. For example the phosphoinositide- dependent kinase 1 (PDK1) and 
PDK2 phosphorylate Akt at  Thr308 and at the Ser473, respectively and thereby activate 
the kinase. Activated Akt can activate or inhibit in turn various target proteins via 
phosphorylation and thus regulates cell cycle progression, survival and metabolism 
(Marone, Cmiljanovic et al. 2008).  
 
Figure 1: Phosphoinositide 3-kinase pathway. Modified from (Gunzl and Schabbauer 2008) 
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PI3K signaling in mammalian immune cells can be induced by cytokines, 
chemokines, immunglobulins and antigens. Proliferation, differentiation, survival, 
chemotaxis, phagocytosis and degranulation can be modulated by this signaling pathway. 
For example PI3K augments the B-cell receptor mediated Ca2+ increase in B-Cells via the 
recruitment of Phospholipase C γ2 (PLCγ2) to the plasma membrane due to its PH- 
domain (Fruman and Cantley 2002). Moreover the membrane compound 
lipopolysaccharide (LPS) of gram negative bacteria can activate the PI3K pathway via the 
TLR4/MyD88 signaling. The LPS mediated signaling induces the phosphorylation of Akt 
(Laird, Rhee et al. 2009). 
For osteoclasts and dendritic cells the TNF family member TRANCE (RANKL) is an 
important functional regulator and acts via the induction of Akt through TNF receptor 
associated factors 6 (TRAF6), c-Src and the PI3K signaling pathway (Wong, Besser et al. 
1999). The PI3K inhibitor wortmannin suppresses the production of PIP3 in neutrophils in 
response to the stimulation with the chemotactic protein formyl peptide. Indicating a role of 
the PI3K in chemotaxis (Okada, Sakuma et al. 1994).  
The knockout of the three regulatory subunits of the class I PI3K p85α, p85β or p55γ is 
perinatal lethal and exhibits dramatic necrosis of hepatocytes and brown fat tissue as well 
as calcification of the cardiac tissue (Fruman, Mauvais-Jarvis et al. 2000). 
The activity of PI3K is counteracted by two phosphatases: the SH2 domain- 
containing inositol phosphatase (SHIP) and the phosphatase and tensin homolog deleted 
in chromosome ten (PTEN). SHIP and PTEN dephosphorylate PIP3 to PtdIns(3,4) P2 and 
PtdIns (4,5)P2, respectively. In this context PTEN is a tumor suppressor gene and mutated 
in different kinds of tumors (Marone, Cmiljanovic et al. 2008).  
PTEN consists of the phosphatase and C2 domains, which are capable of binding lipids. 
PTEN dephosphorylates the 3-positon of the inositol ring and its predominantly target in 
vivo is the PI(3,4,5)P3. Additionally it removes phosphate residues of PI(3)P and PI(3,4)P2.  
The activation state of PTEN can be regulated via phosphorylation. Phosphorylation 
of PTEN potentially induces a closed, more stable conformation with decreased 
competence to bind its substrates. The PI3K downstream kinase glycogen synthase 
kinase 3β (GSK-3β) can phosphorylate the Ser362 and Thr366 of PTEN and thus down 
regulate the catalytic activity of PTEN. Phosphorylation by GSK-3β is promoted by a 
previous phosphorylation of PTEN by CK2. This inhibition provides a negative feedback 
loop of the PI3K signaling (Gericke, Munson et al. 2006).  
 
Introduction 
19 
4.1.5. Arginase 1 
A second important pathway during an immune response is the metabolism of L-
arginine. The two for the substrate competing enzymes the Arginase 1 (Arg1) and the 
inducible nitric-oxide synthase (iNOS, NOS2) are responsible for the conversion of L-
arginine in murine myeloid cells (Bronte and Zanovello 2005).  
Arg1 hydrolyses the amino acid to L-ornithine and urea. L-ornithine is further 
converted into polyamines and L-proline by the ornithine decarboxylase (ODC) and the 
ornithine aminotransferase (OAT), respectively (see Figure 2). Polyamines are small 
cationic molecules and support cell growth and differentiation while L-proline is important 
for the collagen synthesis therefore suggesting an involvement in fibrosis (Bronte and 
Zanovello 2005). The enzymes argininosuccinate synthase and the argininosuccinate 
lyase are able to recycle L-arginine from L-citrulline (Munder 2009).  
Two isoforms of Arginase are known. The Arg1 is expressed in the cytosol of 
hepatocytes and participates in the urea cycle. IL-4, IL-13 (Munder, Eichmann et al. 1999) 
and TGF-β (Boutard, Havouis et al. 1995) can stimulate the Arg1 expression in myeloid 
cells in mice. The transcription factors signal transducer and activator of transcription 6 
(STAT6) and STAT1 are the main players in the transcriptional activation of Arg1. The 
second isoform Arg2 is constitutively found in the mitochondria of renal cells, neurons, 
macrophages and enterocytes (Bronte and Zanovello 2005). In contrast to murine 
leukocytes in human only granulocytes express Arginase 1 constitutively. Stimulation with 
IL-4 and IL-10 failed to increase Arginase 1 expression. Additionally the localization is 
different, because human granulocytes store Arginase 1 in azurophil granules and exhibit 
fungicidal properties (Munder, Mollinedo et al. 2005).  
The nitric-oxide synthase (NOS) is composed of the oxygenase and reductase 
domain and its cofactors (6R)-5,6,7,8-tetrahydrobiopterin (BH4), haem, flavin-adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN). In addition calmodulin is required for 
the conversion of L-arginine to L-citrulline and nitiric oxide (NO). NO can be further used 
to produce superoxide (O2
-), hydrogen peroxide (H2O2) or peroxynitrites (ONOO
–), which 
induce damage to lipids, proteins and DNA (deoxyribonucleic acid) (Bronte and Zanovello 
2005).  
In murine macrophages, neutrophils, eosinophils, dendritic cells (DCs) and natural 
killer cells iNOS is present, however two further isoforms of NOS are known. NOS1 or 
nNOS and NOS3 or eNOS are expressed in the neuronal tissue and endothelial cells, 
respectively. In addition they exhibit differences in their regulation, intracellular localization 
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and catalytic features. Binding of LPS, IFN-γ, IL-1, TNF, IFN-α or IFN-β to their receptors 
lead to the expression of iNOS via different transcription factors, for example the nuclear 
factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB), activator protein 1 (AP1), 
IFN-regulatory factor 1 and STAT1 (Bronte and Zanovello 2005). 
 
Figure 2: L-arginine conversion by Arginase versus iNOS in murine myeloid cells (Munder 
2009).  
 
Due to the differential activation Arg1 and iNOS by type 2 (such as IL-4, IL-13) and 
type 1 (for instance IFN-γ) cytokines, they can be used as marker for alternative (M2) or 
classically (M1) activation of macrophages, respectively (as will be further explained 
below). In contrast, LPS was shown to induce both enzymes, although it is considered as 
inducer of a T helper cell type 1 (TH1) response (Bronte and Zanovello 2005).  
Arg1 activity can cause a depletion of L-arginine in its microenvironment. This effect 
down regulates the expression of CD3ζ (cluster of differentiation 3ζ) of the TCR, thus 
blocks T-cell proliferation (Bronte and Zanovello 2005). The precise mechanism remains 
to be identified. Lack of amino acids can inhibit translation of messenger ribonucleic acid 
(mRNA), due to uncharged transfer RNAs (tRNAs) (Baniyash 2004).  
Stimulation of Arg1 and iNOS at the same time does not negatively influence each 
other, but the diminution of L-arginine shifts the production from mainly nitric oxide 
towards mainly superoxide by iNOS (Bronte and Zanovello 2005).  
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4.2. Plasticity of Immune Cells 
A very important way how the immune system provides adequate host defense, 
without self-damage, is the phenotypical and functional adaptation of immune cells 
according to the immune reaction. Cell types of the immune system – such as T-Cells – 
form various subpopulations – for example TH1 cells – with differences in their phenotype 
and function. Combined stimuli – for instance cytokines – induce their differentiation and 
can even lead to the conversion from one subtype into another. The next sections will deal 
with the plasticity of macrophages, DCs and T helper cells (Galli, Borregaard et al. 2011).  
4.2.1. Macrophages 
Macrophages are derived from the myeloid progenitors of the hematopoietic stem 
cells and differentiate in most cases directly through monocytes in the blood to specific 
tissue macrophages by entering the tissue, such as alveolar macrophages (AMs), Kupffer 
cells or osteoclasts. Therefore they are characterized according to their anatomical 
location. Activation of macrophages initiates a change in expression of pattern-recognition 
receptors resulting in different functional phenotypes, known as macrophage plasticity. 
Different microbial molecules can lead to a mixture of macrophages that vary in their 
capacity of phagocytosis and cytokine expression. The two best known functional 
phenotypes which are also the extremes of a spectrum are the classically activated 
macrophage (M1) and the alternatively activated macrophage (M2) (Biswas and 
Mantovani 2010). Further functional phenotypes are regulatory macrophages, tumor 
associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs) (Galli, 
Borregaard et al. 2011). TAMs share some features with M2 polarized macrophages and 
promote tumor progression, for example by suppressing adaptive immune responses 
(Biswas and Mantovani 2010). MDSCs are considered to have similar function like TAMs 
(Galli, Borregaard et al. 2011).  
 Classically Activated Macrophages 
The M1 phenotype is characterized by the elevated expression of major 
histocompatibility complex II (MHCII) and the costimulator CD86, interferon γ (INF-γ) 
receptor and TLRs (see Figure 3). Damage associated molecular patterns, pathogen 
associated molecular patterns (Galli, Borregaard et al. 2011) and the TH1 cytokine INF-γ 
induce a polarization of macrophages towards M1 phenotype (Biswas and Mantovani 
2010). This is achieved by the INF-γ receptor stimulating IRF/STAT signaling via IRF-5 
and STAT1 and by the TLR4 through NF-κB and IRF-3 (Sica and Mantovani 2012). In a 
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feedback loop M1 macrophages mainly communicate with TH1-Cells by releasing IL-12 
and the chemokines CXCL 9 (chemokine (C-X-C motif) ligand 9) and CXCL 10 and 
thereby inducing inflammation (Biswas and Mantovani 2010). 
 
 
 
Figure 3: Phenotypical characterization of M1 macrophages and its communication with Th1 
cells and NK cells. Reactive nitrogen intermediates (RNI), reactive oxygen intermediates (ROI). 
(Biswas and Mantovani 2010) 
 
Their main function is the phagocytosis of microbes, and further to present their 
antigens to lymphocytes and to eliminate the pathogens (Biswas and Mantovani 2010). In 
the lysosome of the macrophages reactive nitrogen intermediates and reactive oxygen 
intermediates are produced. After microbial uptake the lysosome can fuse with the 
phagosome. In the phagosome these intermediates harm the pathogen (Desjardins, Celis 
et al. 1994; Biswas and Mantovani 2010). Thus classical activated macrophages are very 
important for the clearance of intracellular pathogens (Sica and Mantovani 2012). 
An additional feature of M1 macrophages is that they sequester iron by repressing 
ferroportin (Biswas and Mantovani 2010), which transports iron into the serum 
(Schimanski, Drakesmith et al. 2005) and inducing H ferritin (Biswas and Mantovani 
2010), an intracellular storage molecule (Ratledge and Dover 2000). In contrast to other 
nutrients – such as glucose, nitrogen or phosphate – the essential iron is inaccessible for 
pathogens in the host. This is possible because iron is bound to the glycoprotein 
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transferrin in the blood and the aerobic condition push free iron in the ferric oxidation state 
and thus it is insoluble (Bachman, Miller et al. 2009). Therefore pathogens have 
developed mechanisms for iron uptake, for example siderophores. Siderophores are tiny 
hydrophobic molecules that bind soluble iron with much greater affinity than mammalian 
proteins (Ratledge and Dover 2000).  
 
 Alternatively Activated Macrophages 
The expression of scavenging (SR), folate (FR), mannose (MR) and galactose (GR) 
receptors, CD23 (Biswas and Mantovani 2010), and CD163 (Gordon 2003) characterizes 
alternatively activated macrophages (M2) (see Figure 4) (Biswas and Mantovani 2010). 
Additional markers are IL-1 decoy receptor and IL-1RA, which neutralize the pro-
inflammatory effects of IL-1 (Gordon 2003). In vitro studies showed that IL-4 induces 
proliferation on a low level (Gordon 2003) and the expression of MHC class II (Gordon 
2003). IL-4 can promote the fusion of monocytes and macrophages to giant 
multinucleated cells – which for example have a role in removing foreign particles 
(McInnes and Rennick 1988), by supporting cell adhesion through an increased 
expression of E-cadherin (Sica and Mantovani 2012). Moreover Arginase 1 expression is 
elevated compared to classically activated macrophages, and thus induces a higher 
generation of ornithine and polyamines and therefore is an additional hallmark (Biswas 
and Mantovani 2010).  
Two more M2 indicators are Ym1 and FIZZ1. Ym1 (in human known as chitinase-3-
like protein 3 (CHI3L3)) belongs to the mammalian chitinase-like protein family and is 
STAT6 dependent induced during TH2 responses. Ym1 has evolutionary lost its ability to 
bind chitin and thus its chitinolytic activity (Reese, Liang et al. 2007). FIZZ (found in 
inflammatory zone 1, resistin-like molecule α (Relm α)) is a cysteine-rich protein secreted 
by macrophages, endothelial and epithelial cells (Gordon and Martinez 2010). Based on 
FIZZ deficient mice studies have shown that the lack of FIZZ increases pulmonary 
inflammation and fibrosis, and promotes M2 differentiation of macrophages. In vitro 
recombinant FIZZ is able to inhibit type 2 cytokines of T-cells (Nair, Du et al. 2009). 
 
 
 
 
Introduction 
24 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Phenotypical characterization of M2 macrophages and its communication with 
TH2 cells, basophils and innate lymphoid cells. (Biswas and Mantovani 2010) 
 
M2 polarized macrophages attract TH2-Cells by the release of CCL17 (chemokine 
(C-C motif) ligand - 17), CCL22 and CCL24, which conversely promote a M2 phenotype 
by the secretion of IL-4, IL-13 or IL-33. Furthermore basophils and innate lymphoid cells 
release IL-4 and IL-13 promoting M2 polarization, respectively. Similarly to TH2 cells they 
are also recruited by CCL17, CCL22 and CCL24. Another characteristic of alternatively 
activated macrophages is the low production of IL-12 and the increased in IL-10, which 
has an anti-inflammatory effect and is additionally an important communication molecule 
between TREG-Cells and macrophages. Macrophages can recruit TREG-Cells by the 
secretion of CCL22 (Biswas and Mantovani 2010).  
B-cells can influence the activation of macrophages either through antibodies, 
immune complexes or via cytokines. Immune globulins (Ig) are able to bind the fragment 
crystalline receptor for immunoglobulin G (FcγR) of macrophages and restrain TLR4 and 
type I interferon signaling through the spleen tyrosine kinase (Syk). The FcγRIIb triggers 
the formation of prostaglandin E2, thus reduces the expression of the pro-inflammatory 
cytokines IL-6 and TNF. Immune complexes are immune globulins that are bound to 
antigens (Shmagel and Chereshnev 2009). Together with IL-1 or LPS, immune complexes 
can induce a M2 like phenotype, characterized by a low expression of IL-12 and a high 
production of IL-10 and CCL1, which interacts with eosinophils, polarized TH2-Cells and 
TREG-cells via CCR8 (Biswas and Mantovani 2010).
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M2 macrophages participate in the immune reactions against helminthes and in 
allergic reactions. In the gut, alternatively activated macrophages stimulate clearance of 
extracellular parasites (Galli, Borregaard et al. 2011). Based on their characteristic to 
dampen immune responses and to support tissue remodeling, they are considered to 
have anti-inflammatory and immune regulatory effects. Alternatively activated 
macrophages produce IL-8, epithelial growth factor (EGF), vascular endothelial growth 
factor- A (VEGF-A) and VEGF-C and thus induce angiogenesis and lymphangiogenesis. 
In this context they sustain tumor progression, in contrast to M1 polarized phagocytes 
(Biswas and Mantovani 2010).  
M2 macrophages differ in their iron metabolism from M1 cells, because they 
promote the upregulation of ferroportin. This leads to an increase in the iron levels in the 
plasma and supports cell proliferation (Biswas and Mantovani 2010). 
An additional feature of macrophages is their participation in wound healing. 
Following platelet degranulation macrophages are attracted and secrete cytokines, 
chemokines, matrix metalloproteinases (MMPs) and the tissue inhibitor of 
metalloproteinases (TIMPs). In this regard they influence the remodeling of the 
extracellular matrix (Galli, Borregaard et al. 2011).  
IL-4 induced gene expression starts with the binding to the type I IL-4 receptor – 
composed of IL4Rα or IL4Rγc – or to the type II IL-4 receptor – composed of IL-4Rα or 
IL13Rα1. In contrast, IL-13 can only act through type II IL-4 receptor. This difference in 
receptor binding provides them a variation in their impact. Downstream effects of the 
activation of IL-4 receptors induce STAT6 signaling through diverse Janus kinases. 
STAT6 leads to the expression of peroxisome proliferator-activated receptor γ (PPAR-γ) 
and together they activate M2 associated genes. Further IL-4 triggers the activation of 
jumonji domain containing 3 (JMJD3), a histone demethylase, which stimulates the 
expression of Arg1, Ym1 and FIZZ. JMJD3 acts through methylating the histone 3 at the 
lysine 4 (H3K4) and demethylating H3K27 in their promoter region, thus inducing gene 
expression. In addition JMJD3 inhibits the Toll-like receptor 4 signaling, by stimulating the 
transcription factor interferon regulatory factor 4 (IRF4), which attaches to the adaptor 
molecule MyD88. IRF4 plays also an important role in the regulation of Arg1, Ym1 and 
FIZZ (Biswas and Mantovani 2010). 
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4.2.2. Dendritic Cells 
Dendritic cells derive from hematopoietic stem cells and are professional antigen 
presenting cells. Novel findings indicate that DCs originate from the common myeloid 
precursor (CMP) as well as from the common lymphoid progenitor (CLP). Both 
progenitors can differentiate into macrophage-DC progenitors (MDP), which give rise to 
different DC populations (Figure 5) (Kushwah and Hu 2011). 26 diverse DC populations 
are characterized according to their expression markers. They were isolated from 
lymphoid and non-lymphoid tissue (Miller, Brown et al. 2012). 
An additional possibility to characterize DCs is the differentiation between steady-
state conventional DCs and non-conventional DCs. In contrast to steady-state 
conventional DCs, non-conventional DCs emerge during inflammation. Both types include 
different subtypes (Kushwah and Hu 2011).  
Conventional steady-state DCs include migratory DCs, which reside in the 
peripheral tissues and migrate toward the lymph nodes after antigen uptake. For example, 
in the lung three different subtypes are known, which are present in the intraepithelial 
network or in the lamina propria of the conducting airways. In addition to the migratory 
DCs conventional steady-state DCs consist of lymphoid DCs, which are found in the 
lymphoid organs (Kushwah and Hu 2011).  
Non-conventional DCs comprise plasmacytoid DCs and monocyte-derived DCs. 
Plasmacytoid DCs are not restricted to lymphoid or peripheral organ. They are able to 
rapidly produce INF-γ, maintain tolerance and are involved in autoimmune responses. 
Monocyte-derived DCs are located in the peripheral tissues and appear under steady-
state conditions as well as during inflammation (Kushwah and Hu 2011). 
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Figure 5: Differentiation pathways of dendritic cells. (Kushwah and Hu 2011) 
 
4.2.3. T Helper Cells 
Naïve CD4+ T helper cells emerge from the lymphoid progenitor and can 
differentiate into various subsets. These subpopulations are characterized by their 
cytokine expression pattern and their corresponding effector functions. Frequently, single 
cells of a lineage fail to produce all representative cytokines of their lineage, instead every 
cell express a few and together they specify the population. These cytokine expression 
differences may be mediated by nuclear factor of activated T-cells (NFAT) and epigenetic 
factors. There are four TH cell lineages TH1, TH2, TH17 and TREG-cells. A few more 
lineages – such as TH3, TH9 or T follicular helper cells (Tfh cells) – are discussed, but 
supposedly they are only subsets of the four named previously (Zhu and Paul 2010). 
 
 TH1 Cells 
Immune responses against intracellular pathogens are mainly triggered by TH1 
cells. The cytokines IL-12 and INF-γ are responsible for the differentiation of T helper cells 
toward TH1. Further involved in the differentiation are the transcription factors STAT4 and 
interferon regulatory factor (IRF-1), because the lack of these transcription factors leads to 
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the absence of TH1 cells. IRF-1 modulates the expression of IL-12 of antigen presenting 
cells and thus contributing to TH1 differentiation. An additionally involved transcription 
factor is T-box expressed in T cells (T-bet) of the T-box family. In contrast to STAT4 and 
IRF-1, T-bet is restricted to thymocytes and TH1 lymphocytes and is regulated by the 
signaling of the T cell receptor. T-bet is potent in the activation of the INF-γ transcription 
and in the inhibition of IL-4 and IL-5 expression (Szabo, Kim et al. 2000).  
The hallmark of TH1 cells is the production of INF-γ, which activates macrophages 
and polarizes them toward M1 macrophages. In addition they are able to produce LTα, IL-
2 and TNFα. TH1 cells can change their phenotype into a TH2 phenotype in response to 
IL-4. This effect is only possible in vitro, if they were primed for one round; at later stages 
they maintain their expression pattern (Zhu and Paul 2010). 
 
 TH2 Cells 
TH2 cells are the main actors in the immune reaction against extracellular 
pathogens, parasites and in allergies. IL-4 together with IL-2, IL-7 and the thymic stromal 
lymphopoietin (TSLP) triggers TH2 polarization through GATA3 and STAT5 and is 
sustained by GATA3 and Gfi-1 (Zhu and Paul 2010). GATA3 is strongly expressed during 
the development of TH2 cells and diminished in TH1 cells. Binding of GATA3 to the GATA 
Site of the IL-5 promoter is necessary for the expression of the type 2 cytokine IL-5 
(Zhang, Cohn et al. 1997). An additional transcription factor c-Maf, which is specific for 
TH2 cells, can together with NFAT and NIP45 (NFAT interacting protein 45) stimulate B 
lymphoma cells to produce IL-4 (Hodge, Chun et al. 1996). The lack of c-Maf leads to 
restrained expression of IL-4, whereas other TH2 cytokines, such as IL-5, IL-10 and IL-13 
are still present (Kim, Ho et al. 1999).  
Mature TH2 cells express IL-4, IL-5, IL-10 and IL-13 (probably also IL-25), which 
induce IgE generation and recruit eosinophils. Similar to TH1 cells, TH2 cells can turn into 
TH1 cells after exposure to IL-12, if they are primed only once in vitro. In later stages of 
maturation they lose this plasticity. Stimulation with TGF-β leads to a repression of IL-4 
and an induction of IL-9 (Zhu and Paul 2010). Retroviral expression of T-bet reverses the 
TH2 polarization into TH1 polarization, indicated by the drop of IL-4 and IL-5 production 
and the initiation of INF-γ expression (Szabo, Kim et al. 2000). 
 
Introduction 
29 
 TH17 cells 
TH17 cells participate in the immune reaction against fungi and extracellular 
bacteria. TGF-β together with IL-6, IL-21 and IL-23 induce the differentiation of naïve 
CD4+ T cells into TH17 cells, by the activation of the transcription factors retinoic acid 
receptor orphan nuclear receptor (RORγt) / STAT3. The maturation leads to the 
production of IL-17a, IL-17f, IL-21 and IL-22. Subsets of TH17 cells are found to generate 
IL-9 or IL-10. TH17 cells show the greatest plasticity among the TH cell lineages. Even 
after several rounds of TH17 priming they are able to express – additional to their IL-17 
production – INF-γ or IL-4, after exposure to IL-12 or IL-4, respectively (Zhu and Paul 
2010).  
 TREG-Cells 
Naturally occurring regulatory T cells originate from the thymus in the presence of 
IL-2 and TGF-β. Additionally CD28 co-stimulation and self-recognition support their 
development. Further IL-2, TGF-β and stimulation of the TCR can prime naïve T helper 
cells to develop into inducible regulatory T cells in the periphery. The transcription factors 
forkhead box P3 (Foxp3) and STAT5 trigger their maturation. Isolated populations of TREG-
Cell are composed of both the naturally occurring regulatory T cells and the inducible 
regulatory T cells. Possible they exhibit same functions. They mediate self-tolerance, 
dampen immune responses and possibly promote them. Until now no markers have been 
found to discriminate them. TREG-Cells also feature plasticity; a lack of lymphocytes 
induces a decline of Foxp3 and an increase of IL-17 and INF-γ (Zhu and Paul 2010). 
 
4.3. Fibrosis 
Fibrosis is considered as the pathological replacement of functional tissue by 
connective tissue. Well known initiators of fibrosis are viral infections, radiotherapy, 
chemotherapeutic drugs, aerosolized toxins (Wynn 2011) or alcohol (Lieber 1999). In 
contrast there are still unidentified trigger factors such as in idiopathic pulmonary fibrosis 
(IPF) (Wynn 2011). The process of fibrosis often starts with alveolar epithelial cell lesion in 
pulmonary fibrosis (Moore and Hogaboam 2008) or with chemical injury in the liver due to 
its drug metabolizing activities (Mehendale 2005). Subsequently inflammatory cells 
infiltrate the organ and stimulate fibroblast hyperplasia. Their maturation into 
myofibroblasts leads to an extensive collagen and extracellular matrix (ECM) deposition, 
which results in impaired tissue function due to destruction of the tissue architecture. This 
results in an ineffective gas exchange in the lungs (Moore and Hogaboam 2008). The liver 
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develops cirrhosis and shows portal hypertension with reduced perfusion and nodules of 
regenerating hepatocytes. Finally fibrosis results in malfunction of the organ due to the 
replacement of functional tissue by connective tissue. (Bataller and Brenner 2005). 
4.3.1. From Acute to Chronic Inflammation to Fibrosis 
Development of fibrosis has often been connected to dysregulation of wound 
healing. The process of wound healing is important to restore epithelial and endothelial 
function, especially the barrier function and the inhibition of blood loss. The process can 
be divided in three distinct phases; starting with the injury, followed by the inflammation 
and ending up with the tissue repair (see Figure 6). 
In the injury phase inflammatory mediators are produced by the damaged epithelial 
and endothelial cells. These mediators activate the coagulation cascade and recruit 
platelets, leading to the formation of a fibrin clot and platelet aggregation. In order to 
induce leukocyte migration to the site of damage, platelet degranulation occurs, leading to 
vasodilatation of the blood vessels and enhanced permeability of the endothelium. 
Additionally the basement membrane composed of ECM components has to be degraded 
by leukocytes by means of MMPs such as MMP-2 and MMP-9 to perform extravasation. 
Moreover MMPs and their inhibitors (TIMPs) are important for the clearance of 
inflammatory cells and for the instruction to which extent collagen has to be deposited.  
In the inflammatory phase the leukocytes, which have entered the site of damaged 
cells create chemokine gradients to recruit additional immune cells. Macrophages 
phagocyte damaged and dead cells and remove pathogens in case they exist. Moreover 
neutrophils, eosinophils and lymphocytes are recruited, release cytokines and promote 
inflammation (Wilson and Wynn 2009). Further endothelial cell are encouraged for cell 
division and migration toward the lesion and angiogenesis is promoted (Wynn 2008). 
The wound healing process ends with the rebuilding of functional tissue. Wound 
contractions by myofibroblasts, and the fibrin rich scaffold, which directs epithelial and 
endothelial cells, help to reach this aim. Essential in this phase is the passage from 
increased collagen deposition towards a steady-state collagen production. This effect is 
achieved by apoptosis of fibroblasts, decay of inflammation and clearance of leukocytes 
(Wilson and Wynn 2009). 
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Figure 6: Phases of wound healing response and their possible contribution to fibrosis. 
(Wynn 2011) 
 
According to the literature dysregulation of the wound healing response can result in 
chronic inflammation and further in fibrotic disease and is possible the main reason for this 
disease (Wilson and Wynn 2009). In comparison to normal wound healing, where the 
three phases are in sequence, inflammation and tissue remodeling take place 
synchronously in fibrosis (Wynn 2008). Even factors of the injury phase are involved in the 
fibrotic progression. The X-box binding protein-1 and thrombin are found increased in 
patients suffering from IPF, indicating an enhanced clotting and an important role of the 
platelets is this disease. Moreover thrombin induces the differentiation of fibroblasts into 
alpha smooth muscle actin (α-SMA) - positive myofibroblasts, which are the main source 
for collagen in fibrosis. In addition maladjustment of MMPs and TIMPs can contribute to 
increased ECM degradation and thus elevated collagen deposition (Wilson and Wynn 
2009). 
The inflammatory response and the involved cells have a disputed role in fibrosis. 
On the one hand at the beginning of chronic disease inflammation can reduce the fibrotic 
outcome and on the other hand at later time points fibrotic progression can be supported 
through the production of the pro-fibrotic cytokines IL-13 and TGF-β. In contrast 
macrophages and TREG-cells can also contribute to attenuate fibrotic process at later 
stages, by removing fibroblasts and down-regulating TGF-β, respectively (Wilson and 
Wynn 2009).  
In fibrotic tissue the last phase of wound healing, the tissue repair, often sustains. 
Retardation of fibroblast clearance is often noticed. One possibility could be their 
insensibility toward apoptotic inducers, but the precise mechanism remains to be clarified 
(Wilson and Wynn 2009). Instead of resolution of the wound healing process fibroplasia 
occurs and mesenchymal tissue is substituted by connective tissue, which is unable to 
carry out originally tissue function (Wynn 2004). All these effects lead to the 
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predominance of collagen synthesis over its degradation with an increase of total collagen 
and malfunction of the tissue (Wynn 2008). 
4.3.2. Mechanism of Fibrosis 
The development of fibrosis is a complex mechanism, influenced and accompanied 
by many factors, such as myofibroblasts, cytokines and chemokines (Wynn 2008).  
Myofibroblasts play a major role in the pathogenesis of fibrosis, because they are 
the main source of collagen. They derive from various fibroblasts, for example residential 
fibroblasts of the tissue. Moreover epithelial and endothelial cells can give rise to 
fibroblasts via epithelial- mesenchymal transition and endothelial- mesenchymal transition, 
respectively. Additional bone marrow stem cells can differentiate into a fibroblast- like 
cells, the fibrocytes, which circulate in the blood. The specific functions in fibrosis of the 
different subpopulation have yet to be defined (Wynn 2008). Isolated fibroblasts of IPF 
patients exhibit changes in the expression of genes involved in the ECM proteins 
production and degradation. For example the altered expression pattern of β1 integrin, 
which in healthy fibroblasts is responsible for restraining fibroblast proliferation, if it is 
bound to type 1 collagen. Β1 integrin activates PTEN, which further inactivates PI3K-Akt 
signaling, which supports cell survival (Wynn 2011). In the model of radiation induced 
pulmonary fibrosis antibody induced blocking of the integrin αVβ6 has protective effects; 
while bleomycin induced pulmonary fibrosis is increased (described below) in integrin 
αVβ6 knockout mice. The integrin αVβ6 may influence fibrosis via the activation of latent 
TGF-β, thus the inhibition with antibodies may lead to an reduced amount of TGF-β at the 
site of fibrosis (Sheppard 2008).  
Fibroblasts can be activated via PAMPs and PPR, which induces the expression of 
proinflammatory cytokines and the differentiation into myofibroblasts. Since there are 
fibrosis disorders triggered by stimuli different from pathogens, additional mechanism of 
fibroblast activation are proposed. Fibroblast’s autocrine TGF-β, B-cell derived IL-6, Th2-
cytokines and epigenetic changes account for myofibroblast activation (Wynn 2008). 
Important mediators of fibroblast attraction and proliferation are macrophages 
through the production of TGF-β1 and platelet derived growth factor (PDGF). In addition 
they secrete various chemokines and MMPs. It was shown that macrophages differently 
influence the progress of fibrosis dependent on the stage of the disease. Lacking 
macrophages in the early inflammatory phase leads to a decrease of myofibroblasts. In 
contrast in the late phase of remodeling macrophage deficiency results in persistent 
fibrosis, because subpopulations can induce apoptosis in myofibroblasts, remove cellular 
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debris and stimulate MMPs. Taken together macrophages are involved in all stages 
(Wynn 2011). Alternatively activated macrophages are considered as important inducer of 
fibrosis, because of their elevated expression of Arginase 1. Arginase 1 converts L-
arginine into urea and L-ornithine. The enzymes ODC and OAT further use ornithine to 
produce polyamines and L-proline, which are important for cell growth and are substrates 
for collagen synthesis, respectively. In this context Arginase 1 expression is associated 
with increased fibrotic progression. In contrast to NOS, this is thought to reduce 
fibrogenesis because it uses the same substrate L-arginin, but produces L- 
hydroxyarginine, L-citrulline and nitric oxide (Wynn 2004). Interestingly Arginase 1 
deficiency in myeloid cells induces an increase in inflammation and fibrosis in the model of 
Schistosoma mansoni induced liver fibrosis (Pesce, Ramalingam et al. 2009).  
Many cytokines and chemokines participate either in pro- or anti- fibrotic 
mechanisms. The two most important chemoattractants in fibrogenesis are the 
macrophage inflammatory protein 1α (MIP-1 α, CCL3) and the monocyte chemoattractant 
protein 1 (MCP-1, CCL2) (Wynn 2008). Both chemokines recruit phagocytes and are 
produced by macrophages and epithelial cells (Wynn 2008; Deshmane, Kremlev et al. 
2009). They most likely act pro- fibrotic through the stimulation of IL-4 and IL-13. In 
addition the chemokine receptors CXCR4 and CCR7 promote fibrosis through the 
recruitment of fibrocytes (Wynn 2008). Furthermore TLR2 on respiratory epithelial cells 
can promote fibrosis via the induction of IL-27 and the chemokines MIP-1 α, MCP-1 and 
the interferon gamma-induced protein 1 (Kim, Go et al. 2011). In addition the blockage of 
TLR2 attenuates bleomycin induced pulmonary fibrosis and the maturation of DCs (Yang, 
Cui et al. 2009). 
Various fibrotic diseases exhibit increased levels of TNF, mainly produced by 
macrophages. Controversially, TNF inhibitors trigger benefits, although TNF can hinder 
the synthesis of collagen in myofibroblasts (Wynn 2011). 
Due to the inflammation a great quantity of leukocytes are present, which in turn 
support T-cell migration toward the origin of inflammation, activating the adaptive immune 
system. Different kinds of T helper cell subtypes have distinct influences on fibrogenesis. 
Th1 cells are considered to have anti- fibrotic effects, because they are responsible for 
acute inflammation rather than wound healing. In this context Th1 cytokines such as INF-γ 
and IL-12 diminish fibrotic progression. In contrast Th2 cells are regarded to enhance 
fibrosis. Th2 cells mainly participate in the wound healing and tissue repair response and 
therefore increase fibrotic symptoms through their release of the cytokines IL-4, IL-5, IL-13 
and IL-21. In addition Th2- linked genes – such as procollagens I, III and VI, Arginase 1 
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(Arg-1), lysyl oxidase, MMP-2, MMP-9 and TIMP-1 – are involved in fibrogenesis (Wynn 
2008).  
Elevated IL-4 expression in the bronchoalveolar lavage and in the interstitium 
accompanies idiopathic pulmonary fibrosis and cryptogenic fibrosing alveolitis, 
respectively. IL-4 acts on the IL-4 receptor on fibroblast subtypes, inducing the expression 
of collagen type I and III and fibronectin in vitro (Wynn 2008). Studies with IL-4 knockout 
mice demonstrated different IL-4 mediated effects on fibrosis development. Administration 
of a lethal dose of bleomycin leads to a higher mortality rate of IL-4 deficient mice 
compared to wild-type mice due to lung fibrosis. This effect was accompanied with an 
elevated infiltration of T cells in the knockout. In contrast 21 and 28 days post bleomycin 
treatment IL-4 knockout mice exhibit lower amounts of collagen (Huaux, Liu et al. 2003). 
The central effector molecule in fibrosis is IL-13, which operates via the same IL-
4Rα/ Stat6 pathway like IL-4, but with different consequences. Blocking IL-13 depletes 
collagen deposition, although IL-4 synthesis is maintained. In contrast, over-expression of 
IL-13 induces subepithelial airway fibrosis without additional inflammatory mediators. 
However IL-13 can additional act via IL-13Rα2 chain, which was thought to be only a 
decoy receptor, and induce TGF-β1. The production of latent TGF-β1 in macrophages can 
be promoted by IL-13, as well as the synthesis of proteins which activate TGF-β1. In 
contrast IL-13 can also support collagen deposition independent of TGF-β, due to results 
of MMP-9- , SMAD3- and TGF-β1- deficient mice (Wynn 2008). However the importance 
of IL-13 also varies in different fibrosis models. While mice deficient in IL-13 show 
attenuated liver fibrosis in response to Schistosoma mansoni compared to wild-type mice, 
the deficiency has no significant protective effect during bleomycin induced pulmonary 
fibrosis (Wilson, Madala et al. 2010).  
The Th2 cytokine IL-5 recruits and activates eosinophils. It boosts fibrogenesis by 
promoting the expression of IL-13 and TGF-β. Another Th2 cytokine IL-21 stimulate 
fibrogenesis through the induction of Th2-cell migration and survival. In addition it leads to 
a greater expression of IL-4 and IL-13 receptors on macrophages (Wynn 2008). 
TGF-β belongs to the most important contributors in fibrosis. The isoform TGF-β1 
participates more than the two other isoforms TGF-β2 and TGF-β3. Monocytes in the 
blood and tissue macrophages are the main producer and secrete TGF-β as a 
homodimer, which is bound to the latency- associated protein (LAP). LAP inactivates 
TGF-β and has to be removed for the activation of TGF-β. For example by integrin αvβ6 
or MMPs can cleave LAP, which enables TGF-β to bind its receptor, which in turn 
phosphorylates the transcription factors SMAD 2 and 3. As a complex with SMAD 4, they 
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can adjust transcription of target genes, including procollagen I and III. In addition TGF-β1 
is a putative inducer of the differentiation of epithelial cells into myofibroblasts and 
stimulates the activity of fibroblasts and their collagen synthesis. However TGF-β/ SMAD 
signaling pathways independent of collagen production are also proposed (Wynn 2008).  
Macrophages and neutrophils can additionally contribute to fibrogenesis via the 
production of reactive oxygen species (ROS). ROS are created by ROS-generating 
mitochondria and members of the NADPH oxidase family. For instance NOX4 is elevated 
in IPF and mediates myofibroblasts differentiation and ECM protein synthesis. Moreover 
ROS, together with TNF and IL-1β, stimulate the expression of plasminogen activator 
inhibitor 1, which inhibits plasmin/ plasminogen activator systems.  This system is capable 
to degrade ECM components and induce the production of anti-fibrotic functioning 
prostaglandin E2 (Wynn 2011). 
4.3.3. Bleomycin Induced Lung Fibrosis 
The antibiotic bleomycin (BLM) from actinobacteria Streptomyces verticillus is used 
to induce pulmonary fibrosis in mice. First the drug was identified to eradicate cell 
carcinomas and skin tumors (Moore and Hogaboam 2008), because it is able to break the 
DNA double helix (Azambuja, Fleck et al. 2005). Bleomycin is composed of two major 
structures, namely the bithiazole and the pyrimidine and imidazole structure. The first 
structure allows bleomycin to intercalate into the DNA double helix. The second forms an 
activated complex with iron and oxygen, which generates reactive oxygen species (ROS). 
These ROS mediate strain scission and the loss of DNA bases. In addition bleomycin 
provokes lipid peroxidation and in this context leads to cell damage, which results in the 
formation of oedema, infiltration of immune cells and in the end to collagen deposition. 
The adverse effect of causing pulmonary fibrosis is the limiting factor for a cancer therapy 
(Hay, Shahzeidi et al. 1991). Degradation of BLM is performed by the bleomycin 
hydrolase. The low expression of this inactivating enzyme in the respiratory tract is may 
be the reason for the great susceptible of the lung (Moore and Hogaboam 2008). About 
50% of bleomycin is egested by the kidney within four hours (Azambuja, Fleck et al. 
2005).  Due to these findings the drug is used as model for lung fibrosis in different animal 
models – such as mice, rats, rabbits – which showed a dose dependent lung fibrosis 
induction after injecting bleomycin intraperitoneal (i.p.), intravenaous (i.v.), subcutaneous 
or intratracheal (i.t.). May be due to variations in the expression of bleomycin hydrolase, 
different mice strains react different to bleomycin. For example C57Bl/6 mice are more 
prone to bleomycin induce lung fibrosis than Balb/c mice (Moore and Hogaboam 2008).  
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In this study we used the intratracheal route, but modified the application by 
administering bleomycin through the nose leading to a local application (described in 
material and methods). For the i.t. or intranasal (i.n.) induction of fibrosis a single 
administration is efficient, in contrast to an i.v. injection. The etiopathology is characterized 
by a peak after 21 days and is followed by resolution of the pathology. This transient 
nature of the model differs from the human character of the disease (Moore and 
Hogaboam 2008). 
 
4.4. Aim of the Study 
The aim of this study was to address more precisely the contribution of the PI3K and 
PTEN pathway to the development of bleomycin induced pulmonary fibrosis.  
The first purpose was the establishment and the characterization of the phenotype of the 
bleomycin induced lung fibrosis disease model in mice. Subsequently we investigated 
mice with a myeloid cell specific PTEN deficiency based on the Cre/loxP system. 
Therefore the expression of the site-specific DNA recombinase Cre (cyclization 
recombination) was set under the control of the lysozyme M (LysM) gene promoter, which 
is used for the generation of conditional knockout in macrophages and DCs (Hume 2010). 
Based on previously published data, by our group, it can be concluded that myeloid PTEN 
deficient mice show improved survival during  Streptococcus pneumoniae infection with 
reduced levels of TNF-α and elevated levels of IL-10 (Schabbauer, Matt et al. 2010).  
Because of that we were interested in the effects in a chronic inflammatory lung disease 
model. Therefore we investigated the collagen deposition and fibrotic progression. 
Expression of cytokines was analyzed to identify variations in their expression patterns 
and their influence on the development of the disease. Additionally we wanted to 
determine if PTEN deficiency modulates alternative activation of macrophages and if this 
consequence contributes to pulmonary fibrosis.  
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5. Materials and Methods 
5.1. Mice 
In this study eight to twelve week old, sex matched mice were used and were 
compared with a control group of wild-type littermates. The genotype was determined via 
direct polymerase chain reaction (PCR) of in PCR-lysis buffer lysed murine tissue. All 
animal research studies were approved and were confirm with the institutional guidelines 
(BMWF-66.009/0103-C/GT/2007). 
T.W. Mak (Cancer Institute at Princess Margaret Hospital, University Health 
Network, Toronto, Ontario, Canada) kindly supplied floxed PTEN mice (Suzuki, 
Yamaguchi et al. 2001). Floxed Arginase 1 mice were purchased from Jackson 
Laboratory (Maine, USA). The LysM Cre recombinase transgenic mice were a kind gift 
from R. Johnson (University of California San Diego, La Jolla, CA) (Peyssonnaux, Datta et 
al. 2005). The intercrossed mice were backcrossed to a C57BL/6J background for at least 
eight generations.  
 
5.2. Genotyping 
5.2.1. Murine Tissue Lysis 
 Materials 
 For all experiments requiring dH2O was generated by the Deionizer Milli-Q 
Plus PF, Millipore, MA, USA 
 Ear-tag punch (Fisher Scientific, Pittsburg, PA, USA) 
 Lysis Buffer  
12.11 g (100 mM) Tris-Cl [pH 8.0], 18.61 g (5 mM) EDTA [pH 8.0], 0.2 g 
(0.2%) SDS, 11.69 g NaCl (200 mM) were dissolved in 100 ml dH2O. 
 Proteinase K, PCR grade (Roche Diagnostics, Mannheim, Germany) 
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 Procedure 
To be able to perform littermate controlled experiments we cross-bred wild-type and 
conditional knockout mice. The genotype of the offspring was determined by taking 
murine tissue from the ear, which brought along the possibility to recognize the mouse 
again, because holes were punched in the ears and depending on its localization it 
signified a different number. The murine tissue was lysed in 95 µl PCR-lysis buffer and 
5°µl proteinase K. The samples were put into a thermo block (Mixing Block MB-
102|BIOER, Biozym Scientific GmbH, Hess. Oldendorf, Germany) at a temperature of 
55°C and the samples were shook with 650 rpms for 3 hours. After vortexing (Vortex-
Genie 2, Scientific Industries Inc., NY, USA) the samples 1 ml dH20 was added and the 
lysis was stopped by heating the samples up to 99°C for 5 min. Afterwards the lysed 
tissue was centrifuged at 15 000 rpm for 5 min at 4°C (Centrifuge 5417c, Eppendorf AG, 
Hamburg, Germany) and the chromosomal DNA was stored at 4°C. 
5.2.2. Polymerase Chain Reaction PCR 
 Materials 
 5x GoTaqR® Flexi Buffer (Promega, Madison, WI, USA) 
 dNTPs (deoxyribonucleotide triphosphate) (Fermentas, St. Leon-Rot, 
Germany) 
 GoTaqR® Flexi DNA Polymerase (Promega, Madison, WI, USA) 
 Magnesium Chloride Solution, 25 mM (Promega, Madison, WI, USA) 
 PCR adhesive sealing sheets (Eppendorf AG, Hamburg, Germany) 
 Twin.tec PCR 96 well plate (Eppendorf AG, Hamburg, Germany) 
 Procedure 
Out of the lysed murine tissue direct PCR was carried out. Therefore a master mix 
was prepared by mixing 12.875 µl dH2O, 5 µl 5x Green GoTaq
® Reaction Buffer, 2.5 µl 
dNTPs [2 mM], 2.5 µl MgCl2 [25 mM], 1 µl primer mix and 0.125 µl GoTaq® DNA 
Polymerase [5 µg/µl] per each sample. The primer mix was composed of the forward and 
reversed primer with a concentration of 10 pM/ µl each and the sequences can be seen in 
table 1. 2 µl of the lysate were mixed with the master mix. The PCR was completed by the 
Mastercycler epgradient S (Eppendorf AG, Hamburg, Germany) by using the gene 
specific program from table 2.  
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Table 1: Sequences of the PCR primers for genotyping 
Gene Forward primer (5’ 3’) Reverse primer (5’ 3’) 
PTEN CTC CTC TAC TCC ATT CTT CCC ACT CCC ACC AAT GAA CAA AC 
Arg 1 TGC GAG TTC ATG ACT AAG GTT AAA GCT CAG GTG AAT CGG 
Cre 
TCG CGA TTA TCT TCT ATA TCT 
TCA G 
GCT CGA CCA GTT TAG TTA 
CCC 
 
Table 2: Description of the PCR programs 
PTEN/ Cre Arginase 1  
Temperature 
[°C] 
Time  
[s] 
Temperature 
[°C] 
Time  
[s] 
Steps 
94 180 94 180 Activation of polymerase 
94 45 (x35) 94 30 (x35) Denaturing 
60 45 (x35) 60 60 (x35) Annealing 
72 60 (x35) 72 60 (x35) Extending 
72 300 72 120 Last extension 
4 ∞ 4 ∞ Cool down 
 
5.2.3. Gel Electrophoresis 
 Materials 
 50 x TAE buffer  
242 g Tris base, 71.1 ml Glacial acetic acid and 100 ml 0.5 M EDTA [pH 8.0] 
were mixed and filled up with dH2O to 1000 ml. 
 Agarose (Biozym LE Agarose, Biozym Scientific GmbH, Hess. Oldendorf, 
Germany) 
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 Ethidium Bromide (Ethidium Bromide Solution 10 mg/ml, Invitrogen 
Corporation, CA, USA) 
 Gene Ruler™ 1 kb DNA Ladder (Fermentas, St. Leon-Rot, Germany) 
 
 Procedure 
A 0.2% agarose gel was prepared by dissolving 5 g agarose in 250 ml 1x TAE buffer, by 
heating in the micro wave oven (ELIN). After cooling down 25 µl ethidium bromide was 
added and the gel was poured into a gel electrophoresis plate and combs were stuck into 
(peqlab Biotechnologie GmbH, Erlangen, Germany). After the polymerization of the gel 
the samples and the marker were applied and the gel ran at 120 V for 80 min. The UV-
imager (peqlab Biotechnologie GmbH, Erlangen, Germany) was used to take pictures of 
the gel. 
 
5.3. In Vivo Experiments 
5.3.1. Anesthesia 
 Forane® (Isoflurane, Abott Laboratories Ltd., Queenborough, GB) 
 Ketaminol® (Intervet International GmbH, Unterschleißheim, Germany) 
 Xylasol® (Dr. E. Gräub AG, Bern, CH)  
 Ringer’s Solution (B|Braun Medical Inc., Bethlehem, PA, USA) 
 
Forane® is an inhalation narcotic and was used to euthanize by an overdose. The 
sedative was dropped on a tissue paper, which was put into a glass container together 
with a mouse.  
For anesthetizing mice a mixture of Ketaminol®and Xylasol®, known as Hellabrunner 
mixture, was prepared according to table 3. 5 mg/kg Xylasol® and 50 mg/kg Xylasol® were 
injected intraperitoneally. 
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Table 3: Hellabruner mixture 
Hellabrunner Mixture 
Ketaminol® (100 mg/ml) 2 ml 
Xylasol® (20 mg/ml) 1 ml 
Ringer’s Solution 17 ml 
 
5.3.2. Fibrosis Induction 
 Materials 
 Bleomycin Sulfate, Streptomyces verticillus (Calbiochem®, Merck KGaA, 
Darmstadt, Germany) 
 Natrium chloratum physiologicum 0.9% „Meditrade”-Infusionslösung 
(Meditrade Medicare Medizinprodukte GmbH & Co KG, Kufstein. Austria) 
 Method 
Mice were anesthetized with 5 mg/kg Xylasol® and 50 mg/kg Ketaminol® 
intraperitoneally. Bleomycin sulfate was diluted in sterile 0.9% saline solution to a 
concentration of 0.1 iu BLM per 50 µl. Mice were treated with 0.004 iu bleomycin per one 
gram body weight. An intranasal application was achieved by a pipette, and drop per drop 
was applied on the nose of the mouse, which got inhaled immediately.  
 
5.3.3. Clinical Fibrosis Scoring 
To monitor the fibrotic progression the body weight of the mice were documented. 
The first time they were weight in the morning before they were treated with bleomycin. 
Subsequently mice were weight every morning during the experiment. The body weight of 
the first day was used as reference value.  
 
5.3.4. Bronchoalveolar Lavage 
 Materials 
 10 x PBS  
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400 g NaCl, 10 g KCl and 10g KH2PO4 were dissolved in 5000 ml dH2O and 
the pH was adjusted to 7.4. 
 BD VenflonTM 20g A1.26/N (BD Biosciences, Franklin Lakes, NJ, USA) 
 Forane® (Isoflurane, Abott Laboratories Ltd., Queenborough, GB) 
 Syringe 1 ml (VWR International, Vienna, Austria) 
 Method 
Mice were euthanized by an overdose of isofluran. The skin and the thyroid gland 
were removed to reveal the trachea. Afterwards the trachea was jabbed with a 20 g 
venflon and the needle of the venflon was removed and a 1 ml syringe was connected. 
For the isolation of cytokines two times 0.5 ml PBS were squirted into the lung with the 
syringe and recollected by gentle pulling of the plunger. Subsequently the bronchoalveolar 
lavage fluid (BALF) was centrifuged at 1200 rpm for 5 min at 4°C. The supernatant 
containing the cytokines was stored at -20°C and analyzed by ELISA (enzyme-linked 
immunosorbent assay). The cell pellet was either lysed in two fold SDS PAGE sample 
buffer and stored at -20°C or resuspended in TRIzol and preserved at -70°C, the samples 
were examined by western blot or by real time PCR, respectively.  
 
5.3.5. Lung Homogenization 
 Materials 
 2 x Greenberger Lysis Buffer 
The Greenberger lysis buffer was made by mixing 150 mM NaCl, 15 mM Tris 
base, 1 mM MgCl x 6 H2O, 1 mM CaCl2 x 2 H2O in 200 ml dH20. Subsequently 
the pH was adjusted to 7.4, 1% Tritron was added and the buffer was filled up 
to 250 ml with dH20. 
 Protease inhibitor (Roche Diagnostics, Vienna, Austria) 
Complete protease inhibitor cocktail tablets, EDTA free were used and directly 
solved in Greenberger lysis buffer.  
 Screw-cap tubes (Peqlab Biotechnologie GmbH, Erlangen, Germany) 
 Screw-caps (Peqlab Biotechnologie GmbH, Erlangen, Germany) 
 Stainless Steel Beads 5 mm (Quiagen Vertriebs GmbH, Vienna Austria) 
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 Procedure 
After extraction of the four right pulmonary lobes, they were weighed unfrozen. Four 
fold of the weight in mg saline (µl) was added. Subsequently the tissue was homogenized 
by the Precellys 24 (Bertin technologies, Aix-en-Provence, France) with stainless steel 
beads with a diameter of 5 mm. The homogenization was performed with 5000 rpm 4 
times for 20 sec. 100 µl of the homogenate was mixed with 300 µl TRIzol and RNA 
isolation was completed. 600 µl homogenate were merged with 600 µl Greenberger lysis 
buffer and protease inhibitor. After incubating 20 min on ice the samples were centrifuged 
at 1200 rpm at 4°C for 15 min. Afterwards the supernatant was stored at -20°C and used 
for ELISA.  
 
5.3.6. Preparation of Single Cell Suspensions of Murine Lungs 
 Materials 
 Cell strainer 70 µm and 40 µm BD Falcon (BD Biosciences, Franklin Lakes, NJ 
USA) 
 Collagenase I (Gibco®, Grand Island, NY, USA) 
 DNase I ((Gibco®, Grand Island, NY, USA) 
 Fetal calf serum (Invitrogen, Karsruhe, Germany) 
 Serum-free GIBCO™ RPMI Medium-1640 (Invitrogen, Karlsruhe, Germany) 
 Trypan Blue solution (Sigma Chemicals, Balcatta, Australia) 
 
 Method 
Mice were euthanized by cervical dislocation. The lungs and the heart were 
revealed by opening the chest. Afterwards the peritoneum was opened to intersect the 
vena cava. Subsequently the lungs were perfused through the heart with 1 x PBS, by 
pricking into the right ventricle with a 27 g needle. Once the pulmonary lobes turned white, 
the lungs were taken out of the thorax. The lungs were dissected in small pieces and 
incubated in RPMI + 5% FCS with dose DNase I (50 iu/ml) and dose collagenase I (150 
iu/ml) at 37°C for one hour. The digested lungs were pressed through a 70 μm cell 
strainer and centrifuged at 1250 rpm, 4 °C, for 10 min. The pellet was resuspended in 
PBS containing 2% FCS and cells were passed through a 40 μm cell strainer two times 
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with an end volume of 15 ml. Finally the viable cells were distinguished form dead cells by 
trypan blue staining and the viable cells were counted by the means of Bürker-Türk 
counting chamber. 
 
5.4. In Vitro Experiments 
 Materials 
 96-well plates (Iwaki®, Iwaki Europe GmbH, Willich, Germany) 
 BD Connecta Leur-Lok 3 Way Stopcock Blue (BD Biosciences, Franklin Lakes, 
NJ USA) 
 BD VenflonTM 20g A1.26/N (BD Biosciences, Franklin Lakes, NJ USA) 
 Fetal calf serum (Invitrogen, Karsruhe, Germany) 
 Forane® (Isoflurane, Abott Laboratories Ltd., Queenborough, GB) 
 L-glutamine (Invitrogen, Karlsruhe, Germany) 
 1 x PBS 
 PSF (100 U/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml amphotericin) 
 Recombinant Mouse IL-4 (R&D Systems, Minneapolis, USA) 
 Recombinant Mouse IL-13 (R&D Systems, Minneapolis, USA) 
 Serum-free GIBCO™ RPMI Medium-1640 (Invitrogen, Karlsruhe, Germany) 
 Syringe 5 ml and 10 ml (VWR International, Vienna, Austria) 
 
5.4.2. Isolation of Alveolar Macrophages 
In order to isolate alveolar macrophages, mice were euthanized with an overdose of 
isoflurane and the lungs were flushed with PBS. Therefore the trachea was revealed, by 
removing the skin and the thyroid gland. A venflon was used to prick into the trachea and 
the needle of the venflon was detached. The venflon was connected to a three-way 
stopcock, which was further attached to a 10 ml syringe filled with PBS and an empty 5 ml 
syringe. 1 ml PBS was injected into the trachea and in the alveolar space and recollected 
in the 5 ml syringe. This step was repeated ten times.  
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The collected BALF was centrifuged at 1500 rpm for 7 min at 20°C with a brake of 4. 
The supernatant was discard and the cell pellet resupended in GIBCO™ RPMI Medium. 
 
5.4.3. Stimulation of Alveolar Macrophages In Vitro 
Alveolar macrophages were isolated by a bronchoalveolar lavage described above. 
After counting the cells with the Bürker-Türk counting chamber 105 cells per well were 
plated in a 96 well plate. As media GIBCO™ RPMI Medium was used and dosed with 
10% fetal calf serum, 1% PSF and L-glutamine. The cells were incubated overnight at 
37°C and 5% CO2 in the Steri Cycle CO2 Incubator (Thermo Electron Corp., MN 55359, 
USA). On the following day the cells were stimulated with 5 µg/ ml IL-4 and 5 µg/ ml IL-13. 
Different stimulation times were applied dependent on the experiment. After the 
stimulation the supernatant was collected for cytokine determination and the cells were 
lysed with 2 x sample buffer for SDS-PAGE.  
 
5.5. Analytical Methods 
5.5.1. Histology 
 Materials 
 1 x PBS 
 Cover Glass 24 x 24 mm (VWR Vienna, Austria) 
 Ethanol (Merck Merck KGaA, Darmstadt, Germany) 
 Forane® (Isoflurane, Abott Laboratories Ltd., Queenborough, GB) 
 Objective slides Superfrost®/plus (Carl Roth GmbH, Karlsruhe, 
Germany) 
 Paraformaldehyd (Carl Roth GmbH, Karlsruhe, Germany) 
 Praffin wax (Sigma Aldrich Handels GmbH, Wien, Austria) 
 Roticlear® for histology (Carl Roth GmbH, Karlsruhe, Germany) 
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 Procedure 
The left pulmonary lobe was taken for histological section. First the mice were 
euthanized by an overdose of isoflouran. To be able to extract the lung first the skin above 
the chest was removed. Subsequently the peritoneum was opened and the diaphragm 
was removed. Then the chest was opened on the left and right side, so that it could be tilt 
up. Finally the lobes were released by cutting off the blood vessels. After extraction the 
left lobe was fixed with 10% paraformaldehyd in one fold PBS for two days at room 
temperature. Afterwards the lungs were dehydrated, by putting them into 75% ethanol 
overnight, then in 95% ethanol for two hours followed by incubation overnight in 100% 
ethanol. On the following day the tissue samples were put into 100% ethanol at 37°C for 
30 min. The next incubation was in 100% roticlear at 37% for half an hour and then the 
temperature was raised to 60°C and the samples were let there for 30 min. Afterwards the 
tissue was incubated in a mixture composed of roticlear and paraffin wax at a ratio of 1:1 
for 24 hours at 60°C. Finally the bottle was opened for 48 hours at 60°C to let the 
isopropanol evaporate. Subsequently the tissue was embedded in paraffin by the means 
of an embedding machine (HistoStar, Thermo Fischer Scientific, Waltham, USA). The 
precision rotary microtome (Finesse E+, Shandon, Thermo Fischer Scientific, Waltham, 
USA) was used to slice the paraffin blocks. The sections were made with a diameter of 2 
µm. 
 
5.5.2. Hematoxilin and Eosin Stain 
 Materials 
 Eosin Y solution 0.5% in water (Carl Roth GmbH, Karlsruhe, Germany) 
2 ml 10% eosin was mixed with 198 ml 80% ethanol and 500 ml acetic acid 
 Ethanol (100%, 96%, 80%, 70%, 50%) Ethanol (Merck Merck KGaA, 
Darmstadt, Germany) 
 Hamalaum solution acidic acc. to Mayer (Carl Roth GmbH, Karlsruhe, 
Germany) 
 Hydrochloric acid 37% (Carl Roth GmbH, Karlsruhe, Germany) 
 Mounting Medium Roti®-Mount (Carl Roth GmbH, Karlsruhe, Germany) 
 Roticlear® for histology (Carl Roth GmbH, Karlsruhe, Germany) 
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 Procedure 
The slides with the paraffin slices of the lungs were first deparaffinized by two incubations 
in Roticlear for 20 min. Afterwards the slides were rehydrated by incubating them in 100%, 
96%, 80%, 70%, 50% ethanol for 30 sec each. Then the samples were rinsed in distilled 
water for 5 min, followed by the staining with hamalaun solution, which was diluted 1:2 
with distilled water, for 10 min. Subsequently the sections were washed in running tap 
water for 7 min. The staining was controlled under the microscope and then the samples 
were dipped 2 times in 75% ethanol with 0.4% HCl for the decolorization. Then the 
samples were rinsed in tap water for 7 min and the tissues were dehydrated by 
incubations in 50% (30 sec), 70% (30 sec) and 80% (20 sec) ethanol consecutively. Then 
the eosin stain for 2.5 min followed. Afterwards the slides were incubated for 30 sec in 
96% ethanol, then for 2 min in 100% ethanol and cleaned in Roticlear. Finally the tissue 
was mounted with Roti Mount and cover slips were placed on the tissue sections.  
5.5.3. Sirius Red Stain 
 Solutions 
 Acidified water 
5 ml acetic acid (glacial) (Sigma-Aldrich Handels GmbH, Wien, Austria) was 
added to 1000 ml of distilled water. 
 Mounting Medium Roti®-Mount (Carl Roth GmbH, Karlsruhe, Germany) 
 Picro-sirius red solution 
0.5 g Sirius red F3B (C.I. 35782) were solved in 500 ml saturated aqueous 
solution of picric acid. A little amount of solid picric acid was added to ensure 
saturation. 
 Roticlear® for histology (Carl Roth GmbH, Karlsruhe, Germany) 
 Method 
First the paraffin sections on the slides were deparaffinzed by two incubations in 
Roticlear for 20 min each. Subsequently the slides were incubated in 100%, 96%, 80%, 
70%, 50% ethanol for 30 sec each to rehydrate the tissue. After washing the tissue 
samples in distilled water for 5 min, they were stained in picro-sirius red for one hour. 
Afterwards they were washed in acidified water two times for 1 min each. The remaining 
water was removed by filter papers. Then the samples were incubated three times in 
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100% ethanol for 5 min. The last step was the clearance with roticlear for 5 min. Finally 
the tissue sections were mounted with Roti®-Mount and cover slips were put on the top of 
the slide.  
 
5.5.4. Quantification of Histological Sections 
Pictures of the stained histological sections were taken with the microscope 
(Olympus, Vienna, Austria). The collagen deposition according to the Sirius red stain was 
quantified with ImageJ (Abramoff, Magalhaes et al. 2004). First blood vessels were 
excluded to eliminate false positive collagen deposition due to the collagen of the 
adventitia. Then the picture was converted from a RGB format to 8-bite format. For the 
elimination of the background noise the same threshold was set for every picture. The 
amount of particles were quantified by the analyze particles tool, which were compared.  
5.5.5. Hydroxyproline Measure  
 Solutions 
 Acetate citrate buffer 
120 g N acetate trihydrate, 46 g citric acid, 12 ml acetic acid and 34 g NaOH 
were dissolved in 1000 ml dH20 and the pH was adjusted to 6.5. 
 Chloramine T solution 
635 mg chloramines T was dissolved in 10 ml 50% N-propanol. Afterwards  
40 ml acetate citrate buffer and 1.11 ml 10 M NaOH were added. 
 Ehrlich’s reagent 
1.5 g 4-dimethylamino benzaldehyde was added to a mixture of 6.7 ml N-
propanol and 3.3 ml perchloric acid. 
 Hydroxypoline standards 
Out of the stock solution with a concentration of 1 mg/ml standards were 
prepared by diluting the stock solution with 6 M HCl. The standard curve 
consisted of the standard points: 500, 250, 125, 62.5, 31.5, 15.63, 0 µg/ml 
hydroxyproline. 
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 Procedure 
The four frozen right pulmonary lobes were weighed and 900 µl prechilled dH20 was 
added. With the tissue homogenizer (INULA, OMNI TH International, Kennesaw, GA, 
USA) the lungs were homogenized. Between the samples the homogenizer was rinsed in 
distilled water, 96% ethanol and again in distilled water. The homogenate was transferred 
into screw top tubes and 125 µl 50% TCA (trichloracetic acid) were added, vortexed and 
incubated for 20 min on ice. After the precipitation of the protein the samples were 
centrifuged at 6000 rpm for 10 min at 4°C. The supernatant was discarded and 1000 µl 
ice-cold ethanol were added and vortexed. Subsequently the samples were spun 6000 
rpm for 10 min at 4°C again. This washing step was repeated two times. After discarding 
the supernatant the tubes were opened and dried up side down for 10 min. Afterwards 
800 µl of 6 M HCl were added and incubated for 18 hours at 95°C. Subsequently the 
samples were cooled down to room temperature and then vortexed. After a centrifugation 
at 14000 rpm for 10 min at room temperature the supernatant was withdrawed by using a 
1 ml syringe needle and volume was documented. 40 µl of the supernatant were mixed 
with 460 µl Chloramine T solution. In addition 460 µl Chloramine T solution was added to 
the hydroxyproline standards. Both were incubated for 30 min. Afterwards 500 µl Ehrlich’s 
reagent was added and incubated at 65°C for 20 min. After the samples reached room 
temperature the coloring was measured at 550 nm.  
The amount of hydroxyproline (µg/ml) per pulmonary lobe was calculated as follows. 
The concentration (µg/ml) was divided by 1000 multiplied by the documented volume (µl) 
 
 
5.5.6. RNA Isolation with TRIzol 
 Materials 
 Isopropanol waterfree (Fischer Scientific, Waltham, MA, USA) 
 RotiPhenol/ Chloroform (Carl Roth GmbH, Karlsruhe, Germany) 
 TRIzol® Reagent (Invitrogen Corporation, CA, USA) 
 UltraPure DEPC-treated Water (Invitrogen Corporation, CA, USA) 
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 Method 
In order to isolate RNA from tissue samples homogenized tissue samples in TRIzol 
were centrifuged at 12000 g for ten minutes at 4°C and with the supernatant the protocol 
was continued. To the supernatant and direct to the cell samples in TRIzol a fifth of the 
initial volume of TRIzol were added and the samples were mixed for 5 sec and incubated 
for 3 min at room temperature (RT). Subsequently the samples were spun with 12000 g 
for 15 min at 4°C. The water phase was taken and the same amount of isopropanol was 
added, mixed by pipetting and incubated overnight at -20°C. On the next day the samples 
were centrifuged at 12000 g for 10 min at 4°C. The supernatant was discarded and 500 µl 
75% EtOH was added, incubated for 2 h at -70°C and then spun with 12000 g for 10 min 
at 4°C. Afterwards the supernatant was discarded and 500 µl 75% EtOH was added and 
then centrifuged with 12000 g for 10 min at 4°C. The supernatant was removed and the 
pellet was dried at RT. The pellet was dissolved in nuclease free water and solved for 10 
min at 55°C. 
The RNA concentration was measured with the Nano-Drop machine 
(NanoPhotometer® Pearl, IMPLEN, Munich, Germany) and the RNA samples were stored 
at -70°C. 
5.5.7. Reverse Transcription 
 Materials 
 High-Capacity cDNA Reverse transcription Kits, Applied Biosystems, US 
 UltraPure DEPC-treated Water (Invitrogen Corporation, CA, USA) 
 
 Method 
First a master mix was prepared, by mixing 2 µl RT buffer, 0.8 µl dNTP Mix (100 
mM), 2.0 µl RT random primers, 1 µl RNase Inhibitor and 3.2 µl nuclease-free water. 10 µl 
of the master mix were added to 10 µl RNA. RNA samples were diluted and 1 µg RNA 
was transcribed. Subsequently the samples were incubated for ten min at 25°C; 
afterwards they were allowed to stand for 120 min at 37°C. By rising the temperature to 
85°C the reaction was stopped and then cooled down to 4°C. The cDNA was stored at  
-20°C.  
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5.5.8. Quantitative Polymerase Chain Reaction (qPCR) 
 Materials 
 Adhesive PCR foil (Sarstedt, Nümbrecht, Germany) 
 Ethanol 70% and 96% (Merck Merck KGaA, Darmstadt, Germany) 
 Fast SYBR® Green Master Mix (Applied Biosystems, Life Technologies 
Corporation, Carlsbad, California, USA) 
 Multiply PCR-Plates 96 well (Sarstedt, Nümbrecht, Germany) 
 UltraPure DEPC-treated Water (Invitrogen Corporation, CA, USA) 
 
Table 4: Sequences of the used primers for Real time PCR. 
Gene Forward primer (5’ 3’) Reverse primer (5’ 3’) 
KC CCA CAC TCA AGA ATG GTC GC TCT CCG TTA CTT GGG GAC AC 
IL-6 TGC AAG TGC ATC ATC GTT GTT C CCA CGG CCT TCC CTA CA 
Arg 1 AGA GAT TAT CGG AGC GCC TT TTT TTC CAG CAG ACC AGC TT 
FIZZ 
CTG GAT TGG CAA GAA GTT CC CCC TTC TCA TCT GCA TCT CC 
YM1 
TTT CTC CAG TGT AGC CAT CCT T TCT GGG TAC AAG ATC CCT GAA 
MRC1 
CAG GTG TGG GCT CAG GTA GT TGG CAT GTC CTG GAA TGA T 
CCL17 TGC TTC TGG GGA CTT TTC TG ATA GGA ATG GCC CCT TTG AA 
CCL22 TCT GGA CCT CAA AAT CCT GC TGG AGT AGC TTC TTC ACC CA 
iNOS TGA AGA AAA CCC CTT GTG CT TTC TGT GCT GTC CCA GTG AG 
HPRT TCC TCC TCA GAC CGC TTT T CAT AAC CTG GTT CAT CAT CGC 
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 Procedure 
The master mix was prepared as described in table 5. 13.5 μl master mix were put 
into a well with 1.5 μl cDNA. All steps were performed on ice and protected from light. As 
reference gene hypoxanthine phosphoribosyltransferase (HPRT) was applied. Sequences 
of the primers were either looked up in the qPrimer Depot 
(http://mouseprimerdepot.nci.nih.gov/) or were designed with Ensembl (www.ensembl.org) 
and verified via NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequences of the 
used primers can be seen in table 4. 
The PCR was achieved by the StepOne™ Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA). 
 
Table 5: Composition of the qPCR mastermix 
Mastermix 
Reagents μl /sample 
Master mix 7.5 
Forward primer 0.375 
Reverse primer 0.375 
DEPC water 5.25 
  
5.5.9. SDS-PAGE 
 Materials 
 96% Ethanol (Merck Merck KGaA, Darmstadt, Germany) 
 Anti-Chicken IgY HRP Conjugate (Promega, Madison, WI, USA) 
 Anti-Rabbit IgG HRP-linked Antibody (Cell Signaling Technology, Danvers, 
MA, USA) 
 Bio-Rad Filter Papers (Bio-Rad Laboratories Inc., Hercules, CA, USA) 
 Gel Pouring Rack (Bio-Rad Laboratories Inc., Hercules, CA, USA) 
 Immobilion-P PVDF Transfer Membrane (Millipore, Bedford, MA, USA) 
 PlusOne Tween-20 (GE Healthcare, Bio-Science AB, Uppsala, Sweden) 
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 Running chamber and Western Blot Apparatus (Bio-Rad Laboratories Inc., 
Hercules, CA, USA) 
 Skim Milk Powder (Sigma-Aldrich Handels GmbH, Wien, Austria) 
 SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Fisher 
Scientific, Waltham, USA) 
 TEMED (Roth GmbH+Co. KG, Karlsruhe, Germany) 
 
 Stocks 
 APS (10% ammonium persulfate in dH2O.) 
 10 x PBS 
 PBS-T 
PlusOne Tween 20 (GE Healthcare, Bio-Science AB, Uppsala, Sweden) was 
added to 1x PBS in a concentration of 0.5%. 
 Solutions 
 Solution A 
30 g acrylamide and 0.8 g methylenbisacrylamide were dissolved in100 ml 
dH2O. 
 Solution B 
18.2 g tris(hydroxymethyl)aminomethane and 0.4 g SDS were dissolved in 
dH2O and the pH was adjusted to 8.8. 
 Solution C 
6.06 g Tris base and 0.4 g SDS were filled up to 100 ml dH2O. The pH was 
adapted to 6.8. 
 Buffers 
 2x Sample Buffer 
12.5 ml Solution C, 5 ml mercaptoethanol, 11.5 ml 87% glycerol, 2 g SDS and 
5 mg bromphenol blue were filled up to a total volume of 50 ml with dH2O. 
 4x Running Buffer 
12 g Tris base, 57.6 g and 4 g SDS were solved in 1000 ml dH2O 
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 Blotting Buffer 
250 ml 4 x running buffer and 200 ml methanol were filled up to a total volume 
of 1000 ml with dH2O. 
 Stripping Buffer 
12.5 ml Solution C, 350 µl β-mercaptoethanol and 1 g SDS were filled with 
dH2O up to 50 ml. 
 
 Antibodies 
 Phospho-Akt (Ser473) (D9E) XPTM Rabbit mAb (Cell Signaling Technology, 
Inc.) 
 Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb (Cell Signaling Technology, Inc.) 
 Arginase I (C-2): sc-166920 (Santa Cruz Biotechnology, INC.) 
 Anti-Actin antibody produced in rabbit (Sigma-Aldrich Handels GmbH, Vienna, 
Austria) 
 Procedure 
The performance of the sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) was started with the pouring of gels with 10% acrylamide content by the 
means of a gel pouring rack. Therefore for each gel 1.65 ml solution A, 0.8 ml dH2O and 
2.5 ml solution B were mixed. For the induction of the polymerization 10 μl TEMED and 20 
μl APS were added. After pouring the liquid gel between two glass plates 96% EtOH 
helped to remove air bubbles and to smooth the surface. The EtOH was eliminated after 
the polymerization. Then the stacking gel was used to fill up the remaining space between 
the glass plates and a comb was put into it. The stacking gel contained 0.35 ml solution A, 
0.9 ml dH2O and 1.25 ml solution C. 7.5 μl TEMED and 12.5 μl APS induced the 
polymerization.  
The samples were previously suspended in 2x sample buffer and before applying 
the samples on the gel, they were cooked at 99°C for 10 min at 650 rpm. The gel run at 
30 mA until the marker started to separate and subsequently the run was continued with 
60 mA. The run took place in a chamber filled with 1 x running buffer. 
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5.5.10. Western Blot 
Following the protein separation via SDS-PAGE western blot was performed. In this 
context a sponge, 3 filter papers, the gel, a PVDF membrane, 3 filter papers and a sponge 
were placed above each other. Before the membrane was employed, it was equilibrated 
with methanol and then put into blotting buffer. The sandwich was assembled that the gel 
was close to the negative pole and the membrane near the positive pole to allow the 
proteins to move toward the membrane due to their negative charge. The blotting was 
executed in blotting buffer at 4°C and 150 mA for two hours. Afterwards the membrane 
was blocked in 5% skim milk powder dissolved in 0.5% PBS-T for one hour. Then the 
primary antibody was diluted with 5% milk solution and applied overnight at 4°C on the 
shaker.  
On the following day the membrane was washed 5 times with 0.5% 1x PBS-T for 5 
minutes each. Subsequently the secondary antibody, diluted in 5% milk solution, was put 
on the membrane and incubated shaking at room temperature for two hours. After 
washing the membrane 5 times with 0.5% 1x PBS-T for 5 minutes the blot was treated 
with SuperSignal® West Femto Maximum Sensitivity Substrate. The FluorChem® HD2 
Chemiluminesence Imager (Alpha Innotech Corp., San Leandro, CA, USA) was used to 
develop the blot. 
To analyze additional proteins the blot was stripped. Therefore the blot was 
incubated for 35 min at 55°C in stripping buffer. After washing the blot 5 times with 0.5% 
1x PBS-T for 5 minutes it was blocked with 5% milk solution. The following steps of 
antibody incubation and development were performed similar as described before. 
5.5.11. Enzyme Linked Immunosorbent Assay (ELISA) 
 Materials 
 Mouse Interleukin-4 ELISA Ready-Set-Go!® Kit (eBioscience Inc., San Diego, USA) 
 Mouse Interleukin-6 ELISA Ready-SET-Go!® Kit (eBioscience Inc., San Diego, USA) 
 Mouse Interleukin-12 / Interleukin-23 ELISA Ready-SET-Go!® Kit (eBioscience Inc., 
San Diego, USA) 
 Mouse Interleukin-17A (homodimer) ELISA Ready-Set-Go!® Kit (eBioscience Inc., San 
Diego, USA) 
 Mouse Interleukin-33 (IL-33) Ready-Set-Go!® Kit (eBioscience Inc., San Diego, USA) 
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 Mouse Interferon-gamma (INF-γ) Ready-SET-Go!® Kit (eBioscience Inc., San Diego 
USA) 
 Mouse CXCL 1/KC Mab (Clone 48415), Rat IgG2A (R&D Systems, Minneapolis, USA) 
 Mouse CXCL 1/KC Biotinylated Affinity Purified PAb, Goat IgG (R&D Systems, 
Minneapolis, USA) 
 Recombinant Mouse CXCL 1/KC (R&D Systems, Minneapolis, USA) 
 Anti-Mouse TNF alpha Biotin (eBioscience Inc., San Diego, USA) 
 Anti-Mouse TNF alpha (eBioscience Inc., San Diego, USA) 
 Mouse TNF alpha Recombinant Protein (eBioscience Inc., San Diego, USA) 
 MIP-2 Douset ELISA (R&D, Systems, Minneapolis, USA) 
 0.05% PBS-T 
1 x PBS was mixed with PlusOne Tween-20 (GE Healthcare, Bio-Science AB, 
Uppsala, Sweden) 
 Blocking solution  
BSA dissolved in 1 x PBS to reach an 1 % solution 
 TMB 2-Component Microwell Peroxidase Substrate Kit (VWR International, Vienna, 
Austria) 
 2 N H2SO4 
 Streptavidin-HRP (R&D Systems, Minneapolis, USA) 
 F8 Maxisorb Loose Nunc-Immuno Module (Thermo Scientific-Nunc A/S, Roskilde, 
Denmark) 
 
 Procedure 
The enzyme linked immunosorbent assay was started with the coating with the 
coating antibody of the 96-well-plate. The antibody was applied in the concentration 
according to the manufacturer’s manual. The immune globulin was diluted in PBS and 
incubated overnight at 4°C on a plate shaker. 
On the next day the plate was washed with 0.05% PBS-T three times and then the 
unspecific binding sites of the antibodies were blocked with the blocking solution for one 
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hour at room temperature. In the meanwhile the standard curve and the samples were 
prepared. As highest point of the standard curve was 2 µg/ ml and a serial dilution was 
performed by diluting the highest point 1:2 with the blocking solution. The only exception 
was IL-33, which standard curve started with 8 µg/ ml. The samples were either applied 
undiluted or diluted with blocking solution. After three washing steps with 0.05% PBS-T 
the standards and the samples were put on the plate and incubated overnight at 4°C.  
On the following day the ELISA plate was washed again three times and then the 
capture antibody was added, diluted with blocking solution as referred in the 
manufacturer’s protocol. After two hours incubation at room temperature and four washing 
steps streptavidin labeled with horseradish peroxidase was diluted in the same 
concentration as the capture antibody in the blocking solution. The plate was incubated 
with streptavidin for 20 min at room temperature and washed for five times. Subsequently 
the TMB substrate was added for 10 min. Afterwards the enzymatic reaction was stopped 
by adding 2 N H2SO4 and the intensity of the color was measured with the Bio-Tek EL808 
Ultra Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA) at 450 nm and 540 nm 
and a 4 Parameter log-log curve was created to calculate the concentrations of the 
samples. 
5.5.12. Cytospin 
First a bronchoalveolar lavage was performed and the obtained cells were counted 
with the Bürker-Türk counting chamber. The solution was diluted to achieve a suspension 
with 6 x 105 cells per ml.  
Primary the object slides were mounted with a paper pad and the cuvette in the 
methal holder and placed in the cytocentrifuge (Shandon cytospin® 4, Thermo Fischer 
Scientific, Waltham, MA, USA). Then the paper pads were wet by pipetting 50 µl PBS into 
the cuvette and the first run with 550 rpm for 1 min was started. Afterwards 50 µl of the 
cells suspension were filled into the cuvette and were centrifuged at 550 rpm for 2 min. 
Therefore 30 000 cells were applied on the slide. After the spin the slide, the paper and 
the cuvette were detached and the cytospin was dried at room temperature overnight. The 
prepared cytospins were stained with hematoxylin and eosin. 
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5.5.13. Antibody Staining for Flow Cytometry 
 Materials 
 FACS Buffer 
1 x PBS was mixed with FCS to achieve a solution of 2%. 
 Viability dye eFluor 780 (eBioscience, Inc. San Diego, CA USA) 
 Permeabilizing agent: FIX&PERM® Solution A (ADG. Vienna, Austria) 
 
Table 6: List of antibodies used for flow cytometry. 
Antibody Conjugate Isotype Clone Company 
CD3e V500 hamster IgG2 K 500A2 
BD Biosciences, Franklin Lakes, NJ 
USA 
CD45 V500 rat IgG2b K 30-F11 
BD Biosciences, Franklin Lakes, NJ 
USA 
CD8 FITC rat IgG2a K 53-6.7 
eBioscience Inc. San Diego, CA 
USA 
CD11c FITC IgG1, lambda2 HL3 
BD Biosciences, Franklin Lakes, NJ 
USA 
MRC1 FITC rat IgG2a K MR5D3 Biolegend, London, UK, London, UK 
MHCII FITC rat IgG2a,k 2G9 
BD Biosciences, Franklin Lakes, NJ 
USA 
F4/80 FITC Rat IgG2a,k BM8 
eBioscience Inc. San Diego, CA 
USA 
CD11c AF647 IgG N418 Biolegend, London, UK 
MGL2 AF647 rat IgG2a ERMP23 
BD Biosciences, Franklin Lakes, NJ 
USA 
CD19 PE rat IgG2a PeCa1   
Ly6G PE rat IgG2a K 1A8 Biolegend, London, UK 
CD80 
PerCP 
Cy5.5 Arm ham IgG 16-10A1 Biolegend 
B220 
PerCP 
Cy5.5 rat IgG2a K RA3-6B2 
eBioscience Inc. San Diego, CA 
USA 
F4/80 
PerCP 
Cy5.5 rat IgG2a K BM8 Biolegend, London, UK 
CD11b AF700 rat IgG2b K M1/70 
eBioscience Inc. San Diego, CA 
USA 
CD4  AF700 rat IgG2a K RM4-5 
eBioscience Inc. San Diego, CA 
USA 
NK1.1 eFluor 450 mouse IgG2a K  PK136 
eBioscience Inc. San Diego, CA 
USA 
CD90.2 eFluor 450 rat IgG2a K 53-2.1 
eBioscience Inc. San Diego, CA 
USA 
Ly6C BV 570 IgG2c,k HK1.4 Biolegend, London, UK 
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 Method 
Dilution of antibodies and the washing of cells during this procedure were performed 
with FACS buffer. 
A single lung cells suspension was prepared as described above and 106 cells were 
taken out per staining. The cells were centrifuged at 1250 rpm, 4°C, for 5 min (these 
conditions was applied to all subsequent centrifugation steps) and the supernatant was 
discarded. To block unspecific binding sites cells were incubated 15 min with 6 µg normal 
mouse IgG in 30 μl FACS buffer at room temperature. The 50 μl antibody solution per 
staining was added and the cells were incubated for 30 min at 4°C (surface staining). 
Cells were washed three times (two last with PBS only) followed by viability staining using 
fixable viability dye eFlour 780 for 30 min at 4°C. After the final washing step cells were 
resuspended in 300 μl FACS buffer and analyzed using the flow cytometer LSR Fortessa 
(BD Biosciences, Franklin Lakes, NJ USA). 
 
5.6. Statistical Analysis 
The gained values were evaluated with GraphPad Prism 4 software (GraphPad, San 
Diego, CA, USA) by the means of unpaired Student t test. Critical for significant 
differences was a p-value smaller than 0.05 for all experiments.  
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6. Results 
6.1. Establishment and Validation of the Bleomycin Induced 
Pulmonary Fibrosis Model 
In the literature the bleomycin induced pulmonary fibrosis model (BIPF) is one of the 
most well characterized fibrosis models. The drug can be administered i.v., i.p., i.t. and i.n. 
Systemic (i.v. or i.p.) application leads to subpleural scarring, while local application (i.t.) 
results in bronchiolocentric changes, which more resembles pulmonary fibrosis in 
humans. We therefore decided to apply bleomycin locally. Using single application is 
sufficient. Since intranasal application route is less invasive than intratracheal, it was the 
preferred route of application. To test if intranasal administration is equivalent to 
intratracheal we first tested the distribution of intranasally instilled fluids. To address this 
we treated the mice with Evans Blue Dye and monitored the localization of the dye. We 
could detect the dye in the left and right lungs, but the stomach was unstained (Figure 7).  
 
 
 
 
 
 
 
 
After showing that the intranasal treatment localizes only to the lung we compared 
the outcome of intranasally and intratracheally induced pulmonary fibrosis. C57Bl/6J wild-
type mice were treated with BLM and the left lung was harvested after 21 days. To assess 
the collagen content 2 µm lung sections were stained with Sirius Red. While the untreated 
lung exhibited collagen deposition only around blood vessels, the BLM treated lungs were 
streaked with collagen instead of alveoli. Comparing both routes of BLM application no 
differences were observed (Figure 8). In addition two different concentrations 0.05 iu and 
0.15 iu BLM were examined and a dose dependent collagen deposition was monitored 
stomach 
heart In situ 
right lung 
Figure 7: Murine lung (left) and stomach (right) after 
intranasal instillation of Evans Blue Dye. Only the 
pulmonary lobes were coloured. 
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(Figure 9). The collagen content was quantified by ImageJ and demonstrated that both 
application routes lead to a comparable outcome. 
Untreated lung 0.05 iu BLM i.n. 0.05 iu BLM i.t. 
   
Figure 8: Sirius red stained lung sections 21 d post bleomycin instillation. The left lung 
represents a healthy mouse, while in the middle and the right the lung originate from mice treated 
with bleomycin intranasally (i.n.) and intratracheally (i.t.), respectively. 
 
 
Figure 9: Quantification of the area of collagen deposition. Different routes (intratracheally (i.t.) 
and intranasally (i.n.)) and different concentrations (0.05 iu and 0.15 iu) were tested.  
 
Due to our interest in the involvement of immune cells and their effector 
mechanisms in the development of pulmonary fibrosis, we measured different cytokines in 
lung tissue. To examine this we treated wild-type mice with 0.5 iu BLM intranasally and a 
bronchoalveolar lavage was performed after 7 days to measure the cytokines of the 
bronchoalveoar space. Secondly the lungs were removed and homogenized for the 
cytokine measure of the whole lung tissue. In the lung homogenate we found increased 
levels of IL-17, IL-6, MIP-2 and KC, while there were no significant changes in the 
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expression of INF-γ, IL-4, IL-12 and TNFα (Figure 10). Augmented levels of IL-17, KC and 
IL-6 were found in the bronchoalevolar lavage fluid (Figure 11). The increase of IL-17 is 
confirmed in the literature, where it is described that IL-17 may induce neutrophilia and the 
expression of MMP-1 (Wynn and Ramalingam 2012). In addition neutrophil attracting 
chemokines KC and MIP-2 are elevated (Wynn 2011). IL-6 can support fibroblasts and 
together with TGF-β promote differentiation of T helper cells toward TH17 cells (Wynn and 
Ramalingam 2012).  
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Figure 10: Comparison of the cytokine levels between healthy mice and bleomycin treated 
mice. Whole lung tissue was homogenized and cytokines were measured by ELISA. Error bars 
show the standard deviations of the mean. (n.d…not determined) 
n.d. 
n.d. 
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Figure 11: Comparison of the cytokine levels between healthy mice and bleomycin treated 
mice. The cytokines of the bronchoalveolar lavage fluid were measured by ELISA. Error bars show 
the standard deviations of the mean. 
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6.2. PTEN Deficient Alveolar Macrophages Display a 
Decreased Inflammatory Response 
The main aim of this study was to figure out if myeloid cell PTEN has a role in 
pulmonary fibrosis. To address this issue we used mice with homozygote floxed PTEN 
alleles and the Cre recombinase under the promoter of lysozyme M leading to a 
conditional pten knockout. LysM expression is specific for myeloid cells, such as 
macrophages or dendritic cells. In figures myeloid PTEN deficient mice are referred as 
MyPTEN -/- or MyPTEN KO and their wild-type littermates as WT.  
To elucidate the influence of the lack of myeloid cell derived PTEN on immune 
responses, alveolar macrophages were isolated via a bronchoalveolar lavage and 
stimulated with LPS for 10, 30 and 60 minutes in vitro. Actually the deletion of PTEN 
caused an increase in the baseline activity of the PI3K. This result was indicated by the 
detection of phosphorylated Akt and phosphorylated GSK-3β, two downstream kinases of 
the PI3K (Figure 12). The time course analysis demonstrated that PI3K activity was 
enhanced in PTEN deficient alveolar macrophages and that the maximum was reached 
after ten minutes stimulation, while WT macrophages achieved a PI3K activity maximum 
after 60 minutes. Despite the unequal loading the western blot clearly indicates 
hyperactive PI3K signaling. 
 
 
 
Figure 12: Wild-type and PTEN deficient alveolar macrophages were stimulated with LPS. 
The PI3K activity was examined by the phosphorylation of the two downstream kinases Akt and 
GSK-3β. Determination of actin was used as loading control. 
 
   0‘       10‘        30’       60‘        0‘         10’      30’         60‘    LPS 
             WT                                       MyPten 
-/- 
pAkt 
Actin 
pGSK-3β 
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PTEN activity is associated with the expression of pro-inflammatory cytokines, 
shown by previously published data by our group 2010 in the Journal of Immunology 
(Schabbauer, Matt et al. 2010). To rule out if PTEN deletion leads to a down regulation of 
inflammatory genes PTEN deficient alveolar macrophages were stimulated with LPS or 
heat killed Streptococcus pneumoniae for 16 hour in vitro. The conditional knock out led to 
a reduced release of TNFα (Figure 13). In addition the amount of nitric oxide declined, 
indicating a diminished activity of iNOS (Figure 13). This analysis of the data led to the 
question how myeloid cell specific PTEN influences chronic diseases. 
 
 
  
 
 
 
 
6.3. Myeloid PTEN Deficiency Promotes Fibrotic Response in 
Bleomycin Induced Lung Injury 
To investigate whether myeloid PTEN deficiency influence chronic diseases we 
chose bleomycin (BLM) induced pulmonary fibrosis as chronic disease model. Wild-type 
and myeloid PTEN deficient mice were treated with BLM as described in materials and 
methods. The body weight of the treated mice was determined every day for 21 days and 
expressed as percentage of the weight of day zero. The saline treated groups gained 
weight, while the two other groups, suffering from BLM, lost weight (see Figure 14A). The 
strongest decrease in weight was eight days post BLM application. The myeloid PTEN 
deficient mice had a greater response than their wild-type littermates. According to the 
literature the greatest collagen deposition is noticed 21 days post BLM treatment and that 
WT 
Myeloid PTEN 
-/-
 
LPS - + -  LPS - + - 
Hk S. 
pneumoniae 
- - + 
 Hk S. 
pneumoniae 
- - + 
 
Figure 13: Stimulation of wild-type and PTEN deficient alveolar macrophages with 
LPS or heat killed (hk) S. pneumoniae. TNF-α was determined by ELISA and nitrite via 
the NO generation assay. Error bars show the standard deviations of the mean. 
(Schabbauer, Matt et al. 2010) 
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the mice can reach their original weight again during this period. During the three weeks 
both genotypes failed to recover their initial weight, they had on the day of the treatment.  
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Figure 14: Comparison of fibrotic markers between WT and myeloid PTEN KO mice. A) Body 
weight loss of mice after bleomycin administration. B) Hydroxyproline (OH-Proline) content in 
murine lungs 21 day post bleomycin treatment. Error bars show the standard deviations of the 
mean. 
 
21 days after the BLM treatment the left lung was removed and prepared for 
histological analysis. The pathological changes were examined via hematoxylin and eosin 
(H&E) staining to differentiate immune cells (see Figure 15). In addition Sirius Red 
staining was applied to visualize collagen deposition. The H&E staining displayed an 
enormous infiltration of immune cells, such as macrophages and neutrophils. Collagen 
deposition was induced by bleomycin and was increased in the group of myeloid PTEN 
KO mice (see Figure 15). In addition the right lung was used for measuring the 
hydroxyproline levels. Hydroxyproline is the main component of collagen and in mammals 
it is only found in collagen and elastin. In this context the content of hydroxyproline 
indicates the collagen content. Hydroxyproline was elevated in the lungs of myeloid PTEN 
deficient mice after pulmonary fibrosis induction (see Figure 14B).  
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Figure 15: Histological specimen of murine lung tissue. The left column present the control 
lung treated with saline, the middle column demonstrates the lung of a wild-type mouse 21 day 
post bleomycin treatment and the right one covers the bleomycin treated lung of a myeloid PTEN 
knockout mouse. The two upper rows display the collagen deposition via Sirius Red staining. The 
third and fourth rows demonstrate the hematoxylin and eosin staining. Images of each row top-
down are shown at 12.5, 40, 12.5 and 200 x magnification. Tissue was embedded in paraffin and 2 
µm sections were prepared.  
 
We were further interested if this pathological outcome is may linked to differences 
in the amount of immune cell populations. In this context we took mice seven days after 
BLM application and prepared a single cell suspension of the lungs for flow cytometry 
analysis. Therefore the lungs were flushed through the heart, cut in small pieces and 
digested by collagenase 1 and DNase 1. The cell suspension was harvested by filtering 
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the homogenate through a cell strainer. Afterwards the cells were stained with antibodies 
for flow cytometry analysis. The results were evaluated by the following gating strategy: 
first the viable cells were selected according to the viability dye; secondly single cells were 
picked in accordance with the forward and side scatter (Figure 16). This population was 
used for further analysis. To identify B-cells a CD45 positive population was separated 
according to their expression of B220 and CD19. Double positive cells were recognized as 
B-cells and between wild-type and myeloid PTEN deficient mice no differences were 
noticed. CD45 positive, CD90.1 positive and CD3 positive cells were referred as T-cells. 
In myeloid PTEN deficient mice this population was decreased compared to wild-type 
mice seven days after BLM treatment. In contrast, we made the observation that the ratio 
of CD4+ T helper cells and CD8+ cytotoxic T cells was similar. Moreover CD45 positive, 
F4/80 positive and CD11c negative cells, probably interstitial macrophages, and F4/80 
positive and CD11c positive cells, most likely alveolar macrophages, were found to be 
present at similar extent. NK cells were tried to be identified via the expression of CD45, 
CD11c and NK1.1 and exhibited no significant differences. In addition we failed to identify 
any variation between the wild-type and myeloid PTEN deficient mice in the infiltration of 
neutrophils, which were characterized by the expression of CD45, CD11c, and Ly6G. 
Similar amounts of CD45 positive and CD11c positive DCs lacking the expression of 
NK1.1 or Ly6G were noticed. Further no differences were detected in the population 
expressing the TREG-cell marker CD25. 
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Figure 16: Flow cytometric analysis of murine lung cell suspension 7 days post bleomycin 
treatment. Wild-type mice were compared with myeloid PTEN deficient mice. Each genotype is 
represented by two mice. Different markers were applied to identify macrophages, DCs, NK-cells, 
B-cells, T-cells, Th cells, cytotoxic T-cells and TREG-cells. 
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6.4. Cytokines Linked to Inflammation and Fibrosis are Partly 
Elevated in Myeloid PTEN Deficient Mice 
Next we measured cytokines associated with inflammation and fibrosis on protein 
level with ELISA and on mRNA level with Real Time PCR. BALF and lung homogenates 
were used for ELISA, and RNA was isolated from the lung homogenate. The real time 
PCR demonstrated that IL-6 and the chemokine KC were stronger induced in the 
conditional PTEN knockout mice 7 days post BLM treatment (Figure 17). As reference 
gene HPRT was measured. Further we could show that the cytokines INF-γ, IL-4 and IL-
17, IL-12, IL-6, TNF-α, IL-33 were elevated in myeloid deficient mice in the lung tissue 
(Figure 18). In addition the cytokines of the bronchoalveolar lavage fluid were examined 
(Figure 19). The outcome showed that INF-γ, IL-4, IL-17, IL-6 and TNF-α were increased 
similar to the result of the analysis of the whole lung tissue. In contrast decreased levels of 
IL-12 and KC were observed. 
IL-33 is released by damaged epithelial cells and promotes the differentiation of T 
helper cells toward TH2 cells (Wynn and Ramalingam 2012). INF-γ and IL-12 are the 
main cytokines of the TH1 response and are believed to diminish fibrotic progression 
(Thannickal, Toews et al. 2004), in contrast IL-12 stimulates, in addition to the TH1 
response, TH17 cells with profibrotic characteristics (Wilson, Madala et al. 2010). Further 
an over-expression of TNF-α is associated with a severer fibrotic disease (Wynn 2011). 
Nevertheless the inflammatory chemokine KC was not differentially expressed on protein 
level. All together the variations in the cytokine profiles of the two different genotypes 
might indicate that the myeloid PTEN deficient mice developed a more serious 
inflammatory response promoting fibrosis.  
 
  
Figure 17: IL-6 and KC expression 7 days post bleomycin treatment. RNA was isolated from 
lungs of myeloid PTEN knockout mice and wild-type littermates. Error bars show the standard 
deviations of the mean. 
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Figure 18: Wild-type and myeloid PTEN deficient mice were treated with bleomycin for 7 
days and subsequently their lungs were homogenized and analyzed by ELISA. Error bars 
show the standard deviations of the mean. 
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Figure 19: Wild-type and myeloid PTEN deficient mice were treated with bleomycin, at day 7 
the bronchoalveolar lavage fluid was collected and analyzed by ELISA. Error bars show the 
standard deviations of the mean. (n.d…not determined)  
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6.5. IL-4/ IL-13 Stimulation Leads to Enhanced PI3K Activity 
in PTEN Deficient Alveolar Macrophages 
Due to the importance of IL-4 and IL-13 in the pathogenesis of lung fibrosis, we 
elucidated whether these type 2 cytokines are potent to activate PI3K signaling. In this 
context we isolated alveolar macrophages and stimulated them with IL-4 and IL-13 in 
vitro. The time course analysis with the time points: 10, 30 and 60 minutes, showed that 
the two cytokines stimulated the activity of the PI3K albeit at a lower level as compared to 
other activators of the PI3K pathway. This effect was demonstrated by western blotting, at 
which we made the observation that the downstream kinases Akt and GSK-3β of the PI3K 
were phosphorylated in response to the stimulation (Figure 20). Phosphorylation of Akt 
and GSK-3β denotes PI3K signaling.  
Wild-type macrophages exhibited the greatest PI3K activity after 60 minutes. In 
comparison PTEN deficient macrophages displayed activity, that was even higher after 
ten minutes than in wild-types after 60 minutes. The activity seemed to be constantly high 
for the 60 minutes. This result indicated that IL-4 and IL-13 were able to trigger PI3K 
action, but to a lower extent as compared to LPS (Figure 12).  
 
Figure 20: Western Blot analysis of wild-type and myeloid deficient alveolar macrophages 
after 10, 30 or 60 minutes stimulation with IL-4 and IL-13. As target the phosphorylation state of 
the PI3K downstream kinases Akt and GSK-3β were investigated. Actin was used as loading 
control.  
6.6. The Phenotypic Analysis of Naïve Lung Macrophages 
Deficient for PTEN 
Since IL-4 and IL-13 are known to induce a M2 activation state in macrophages and 
the observation that these type 2 cytokines are potent inducers of the PI3K, we were 
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interested if there are baseline differences in the M2 phenotype between wild-type and 
conditional PTEN knockout mice. For that purpose lung cell suspensions of naïve mice 
were generated. After flushing the lung via the heart to remove erythrocytes, the lungs 
were sliced, digested with collagenase 1 and DNase 1 and homogenized with cell 
strainers. The cells were stained with fluorescently labeled antibodies specific for M1 and 
M2 markers. On the one hand we investigated MHCII, the costimulatory molecule CD80 
and Ly6C as surface molecules specific for a M1 phenotype and on the other hand the 
mannose receptor MRC1 and the macrophage galactose N-acetyl-galactosamine specific 
lectin 2 (MGL2) were used to characterize a M2 phenotype. Additionally the cells were 
labeled for viability to be able to exclude dead cells, which would maybe triggered false 
positive signals. For the evaluation of the results following gating strategy was used: first 
the dead cells were excluded via the viability dye and secondly doublets were eliminated 
according to the forward and side scatters. In order to display a macrophage population, 
the next gating step was to take the CD45 positive cells and to separate this population 
according to their expression of CD11b and CD11c. These two markers enabled the 
differentiation between alveolar macrophages, interstitial macrophages and dendritic cells. 
Autofluorescent cells, which were double positive for CD11c and CD11b, were further 
gated for F4/80 and considered as alveolar macrophages. Cells, which expressed CD11c 
but did not express CD11b, were further selected for the presence of Ly6G and assumed 
to be dendritic cells. Non-autofluorescent cells only positive for CD11b were thought to be 
interstitial macrophages. These three populations were examined for their expression of 
the above named M1 and M2 markers. The analysis showed no differences in the relative 
numbers of interstitial macrophages, alveolar macrophages and dendritic cells.  
In addition the comparison of the above mentioned surface markers between the 
wild-type and PTEN deficient alveolar macrophages showed no alterations (Figure 21). 
However the dendritic cells seemed to have also similar expression patterns. In contrast 
the interstitial macrophages differed slightly in their expression of MGL2 and Ly6C. Both 
markers were reduced in mice with a deletion of PTEN in myeloid cells, indicating a 
change in the phenotype of the macrophages, but not a shift toward M1 or M2, because 
markers for both phenotypes were diminished. Since these data are based on a single 
experiment observation, the results need to be further analyzed. 
Moreover we compared the cell composition of wild-type and myeloid PTEN 
deficient mice. The amount of B-cells, characterized by the expression of CD45, B220 and 
CD19, and T-cells, typified by the expression of CD3 out of the B220 and CD19 negative 
population, were comparable. Furthermore the ratio between CD4 T helper cells and CD8 
cytotoxic T cells was similar (data not shown).  
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Figure 21: Flow cytometry analysis of murine lungs for M1 and M2 markers. Interstitial, 
alveolar macrophages and dendritic cells were examined. Gating strategy: excluding of the dead 
cells via the viability dye, elimination of the doublets according to the forward and side scatters, 
taking of the CD45+ cells and separating them according to CD11b and CD11c expression 
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6.7. IL-4 or IL-13 Stimulated PTEN Deficient Macrophages 
Display a M2 like Phenotype 
To further clarify differences in the phenotype of wild-type and PTEN deficient 
macrophages, we analyzed the effects of typical M2 inducing cytokines and S. 
pneumoniae. Alveolar macrophages were isolated and in vitro stimulated with IL-4, IL-13 
or heat-killed bacteria. After 16 hours stimulation the cells were harvested and RNA was 
isolated for Real Time PCR analysis. mRNAs of representative alternative activation 
markers were investigated to identify the functional activation state of these macrophages. 
As reference gene HPRT was used.  
The first gene we examined was Arginase 1. Unchallenged macrophages, 
independent of PTEN expression or deletion, did not express Arginase 1. In contrast the 
stimulation with IL-4 led to its expression and the results showed a tendency of Arginase 1 
to be higher expressed in PTEN deficient macrophages. A significant increased 
expression of Arginase 1 in phagocytes with conditional PTEN knockout was induced by 
IL-13. This was shown by a fold change of 1.056 in contrast to a fold exchange of 0.739 in 
wild-types, compared with unstimulated macrophages. The treatment with heat killed S. 
pneumoniae did not affect the expression profile of this gene.  
As second step we analyzed the expression of FIZZ also referred as Relm-α. PTEN 
deficient macrophages challenged with IL-4 exhibited significantly increased levels of FIZZ 
mRNA (Figure 22). A similar ratio was seen by the stimulation with IL-13, but the induction 
was reduced compared to the IL-4 treatment. Stimulation of alveolar macrophages with S. 
pneumoniae failed to stimulate the expression of FIZZ.  
Furthermore differences of the mRNA levels of YM1 also known as Chi3l3 were 
examined. Investigation of baseline levels of YM1 mRNA indicated that absence of PTEN 
lead to a down regulation of the protein (Figure 22). Although the stimulation with IL-4 and 
with IL-13 initiated the transcription of the ym1 gene, the levels were reduced compared to 
wild-type cells. The bacterial challenge failed to induce YM1 expression and similar to the 
naïve macrophages, PTEN deficient cells had diminished transcription. 
Additionally the expression of the mannose receptor 1 (MRC-1) was studied. 
Unchallenged alveolar macrophages displayed an expression of MRC-1 with a similar 
extent between wild-type and PTEN deficient macrophages (Figure 22). In both genotypes 
the stimulation with IL-4 or with IL-13 lead to the induction of the receptor, but no 
significant differences in the expression were noticed. Similar to the other M2 markers S. 
pneumoniae was unsuccessful in inducing MRC-1 expression. 
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Additionally we analyzed the levels of the two chemokines CCL17 and CCL22 
(macrophage derived chemokine), which participate in the M2 immune response. Naive 
macrophages lacked the expression of CCL17 and only had small levels of CCL22 (Figure 
22). Confronting these immune cells with IL-4 or IL-13 induced the expression of both 
chemokines. The PTEN knockout caused a significantly reduced amount of CCL17 and 
CCL22 after IL-4 treatment, similar to the challenge with IL-13. S. pneumoniae promoted 
only a slightly increase of CCL17 with a tendency that PTEN deficiency diminished CCL17 
expression. CCL22 was additionally stimulated by S. pneumoniae, but no differences 
could be seen between the two genotypes.  
In addition to the M2 markers we also analyzed the expression of iNOS, the 
counteracting enzyme of Arginase 1 and a marker for classically activated macrophages 
(M1). Stimulation of alveolar macrophages with LPS or heat killed S. pneumoniae led to 
the expression of iNOS (Figure 23). The PTEN deficiency triggered a significantly reduce 
in in the expression compared to the wild-type macrophages.  
All these results indicated that the PI3K / PTEN axis influences the phenotype of 
activated macrophages. PTEN deficiency led to an increase of Arginase 1 and FIZZ, but 
in contrast MRC-1 was unchanged and YM1 together with the chemokines CCL17 and 
CCL22 were diminished. Moreover the M1 marker iNOS was also decreased in the 
conditional PTEN knockout cells. 
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Figure 22: mRNA levels of M2 markers of WT and PTEN deficient alveolar macrophages 
after stimulation with IL-4, IL-13 or heat killed S. pneumonia. The levels are expressed as fold 
change of the untreated control. Error bars show the standard deviations of the mean. Not 
determined (n.d.). 
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Figure 23: Expression of iNOS of alveolar macrophages in response to LPS or heat killed S. 
pneumonia. Wild-type mice were compared with myeloid PTEN deficient mice. The levels are 
expressed as fold change of the untreated control. Error bars show the standard deviations of the 
mean.  
 
6.8. In Vitro Stimulation with IL-4/ IL-13 Leads to Increased 
Levels of Arginase 1 in PTEN Deficient Alveolar 
Macrophages 
Due to the importance of Arginase 1 in collagen synthesis, we further wanted to 
proof if the increase in Arginase 1 mRNA can be reflected on the protein level. In order 
following on that idea we took alveolar macrophages of wild-type mice and myeloid PTEN 
deficient mice and stimulated the cells with IL-4 and IL-13 overnight. The cells were 
harvested and lysated in 2 x sample buffer. After the protein separation via SDS PAGE 
and western blotting Arginase 1 was detected with a specific antibody. The experiment 
showed that the cytokines IL-4/ IL-13 induced the expression of Arginase 1 in alveolar 
macrophages (Figure 24). Lack of PTEN caused increased amounts of Arginase 1. 
Therefore this result supported the data about increased Arginase 1 mRNA in PTEN 
deficient alveolar macrophages.  
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Figure 24: Expression of Arginase 1 in wild-type and PTEN deficient alveolar macrophages 
after stimulation with IL4/IL13 overnight in vitro. As loading control actin was applied. 
 
6.9. Arginase 1 Expression is Increased in Myeloid PTEN 
Deficient Mice Post BLM Treatment 
To figure out the importance of alternative activation of macrophages and in 
particular the role of Arginase 1 we examined the expression of Arginase 1 during 
pulmonary fibrosis. Arginase 1 is part of the main markers for alternatively activated 
macrophages, which are considered as drivers of fibrosis (Wynn 2004). The enzyme is 
important for the generation of L-proline, which in turn is required for the collagen 
synthesis by fibroblasts (Wynn 2004). In this perspective wild-type and myeloid PTEN 
deficient mice were treated with bleomycin. After 7 days we isolated cells from treated 
animals, which entered the bronchioles and alveoli, via a bronchoalveolar lavage. 
Examination of H&E stained cytospins indicated that these cells were mainly composed of 
macrophages, neutrophils, basophils and in lower extent lymphocytes (Figure 25).  
 
 
 
 
 
 
 
 
Figure 25: Cytospin of the bronchoalveolar lavage fluid. One example of a macrophage and a 
neutrophil are indicated by a red and black arrow, respectively. 
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These BAL cells were directly lysated in sample buffer for SDS-PAGE and western 
blotting was performed. In saline treated mice of both genotypes Arginase 1 expression 
was undetectable. In contrast, BLM treatment leads to the expression of the enzyme after 
seven days (Figure 26). Three days post BLM application Arginase 1 was not detected 
(data not shown). To further analyze why PTEN deficiency in myeloid cells led to an 
increase in fibrosis, we compared the expression between wild-type and the conditional 
PTEN knockout mice. The western blot showed that mice lacking PTEN in myeloid cells 
produced enhanced levels of Arginase 1 seven days post BLM treatment. 
 
 
Figure 26: Western blot analysis of the expression of Arginase 1 and the release of albumin 
7 days post bleomycin treatment. The expression was compared between myeloid PTEN 
deficient mice and their wild-type littermates. Actin was used as loading control.  
 
6.10. Myeloid Cells are Responsible for the Expression of 
Arginase 1 in BLM Induced Pulmonary Fibrosis 
To elucidate the importance of myeloid derived Arginase 1 during pulmonary 
fibrosis, we used mice with floxed Arginase 1 alleles and created a conditional knockout 
with the Cre recombinase under expression of the LysM promoter. These genetic 
modifications led to a deficiency of the arginase 1 gene only in myeloid cells. Mice with the 
expression of Cre are referred as MyArg1-/- or MyArg1 KO mice in figures. We wanted to 
identify if the Arginase 1 expression during pulmonary fibrosis was due to myeloid cells. In 
this context we treated wild-type and myeloid Arginase 1 deficient mice with 0.1 iu BLM 
intranasally. Seven days after the application the lungs were lavaged via the trachea to 
collect cytokines and cells of the bronchus and the alveoli. The BALF was centrifuged to 
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separate the cells from the fluid and the pellet was resuspended in SDS PAGE sample 
buffer. Western blot analysis showed that Arginase 1 was strongly reduced in the myeloid 
Arginase 1 deficient mice (Figure 27). The little expression was possible due to the 
incomplete knockout. This result indicated that the main producers of Arginase 1 during 
pulmonary fibrosis were myeloid cells.  
 
Figure 27: Illustration of the expression of Arginase 1 and release of albumin by western 
blot analysis 7 days after the bleomycin treatment. In this figure wild-types were compared with 
myeloid Arginase 1 deficient mice. The loading control was actin. 
 
6.11. Myeloid Arginase 1 deficient mice have a reduced 
loss of weight due to BLM application 
Following the idea that myeloid PTEN deficient mice suffered from a severer fibrosis 
due to the elevated Arginase 1 expression, we assumed that the myeloid specific deletion 
of this enzyme may comprise protective features, specifically in our fibrosis model. To 
elucidate this question fibrosis was induced by bleomycin. One parameter for the 
progression of pulmonary fibrosis is the weight and accordingly its loss throughout the 
illness. During the first and the second day after the bleomycin instillation, myeloid 
Arginase 1 deficient mice had a significantly lower weight loss than their wild-type 
littermates (Figure 28). In this experiment we used a dose of 0.3 iu BLM which was to 
high, because the response was too strong that after five days both genotypes had a 
similar weight loss.  
The additional fibrosis parameters such as the concentration of hydroxyproline have 
to be measured again, because the first experiment, in which it was planned to 
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characterize the fibrotic phenotype of myeloid Arginase 1 deficient mice failed due to the 
activity loss of BLM. In that experiment the induction of fibrosis was unsuccessful.  
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Figure 28: Percentage of body weight loss due to bleomycin treatment. The differences of 
the weights were shown from the days one, two and five post bleomycin instillation (from 
left to right) and wild-types and myeloid Arginase 1 deficient mice were compared. Error 
bars show the standard deviations of the mean. 
6.12. Cytokine Profile of Myeloid Arginase 1 Deficient Mice 
in Pulmonary Fibrosis 
To characterize the influence of the deletion of Arginase 1 in myeloid cells on 
pulmonary fibrosis, cytokines were determined seven days post BLM treatment. Due to 
low dose or low bleomycin efficiency and the limited number of mice only a tendency 
could be seen. Bronchoalveolar lavage fluid and homogenized lungs were investigated for 
their cytokine profile.  
No differences were noticed between lung homogenates of wild-type and conditional 
Arginase 1 knockout mice in the levels of IL-12, KC, IL-6 and INF-γ (Figure 29). A small 
trend could be seen in the production of IL-4 and TNF-α, which seemed to be increased, 
while IL-17 gave the impression to be reduced in the lung homogenate of myeloid 
Arginase 1 mice. In the BALF only KC and IL-12 showed a tendency to be reduced in the 
conditional knockout mice, while IL-6 and INF-γ seemed to be produced to a similar extent 
(Figure 30). The amount of IL-17, IL-4, TNF-α and IL-33 were below the detection limit of 
the ELISA. To investigate the potential effects mediated by Arginase 1 deficiency the 
experiments have to be repeated with a larger sample size and maybe with a slightly 
increased dose of BLM. 
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Figure 29: Cytokine levels of lung homogenates of myeloid Arginase 1 deficient mice 
and wild-type littermates 7 days post bleomycin treatment. Error bars show the standard 
deviations of the mean. 
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Figure 30: Cytokines of the bronchoalveolar lavage fluid of myeloid Arginase 1 deficient 
mice were compared with the cytokines of wild-type littermates. The mice were treated with 
bleomycin and after 7 days the lavage was performed. Error bars show the standard deviations of 
the mean. 
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7. Discussion and Perspectives 
Increasing evidence of the influence of the innate immunity and alternatively 
activated macrophages in the pathogenesis of fibrosis triggered our interest, if myeloid 
PTEN contributes to fibrogenesis.  
Previously published data by our group (Schabbauer, Matt et al. 2010) showed that 
myeloid knockout of PTEN leads to a reduced inflammatory response. We showed that 
LPS challenged alveolar macrophages produce lower levels of the pro-inflammatory 
cytokine TNF-α and NO if PTEN is absent. Moreover myeloid PTEN deletion increases 
the survival rate during S. pneumoniae infection. Based on this beneficial effect of 
increased PI3K activity in acute inflammation, we were interested in its influence on 
chronic inflammation. As model we decided to establish the bleomycin induced pulmonary 
fibrosis model. The advantages of this disease model are the high reproducibility, the 
histological analogy to human IPF and the simple application. Due to the clinical use of 
BLM in some cancer therapies, the model adds clinical relevance. In contrast the transient 
character of this model is dissimilar with the human pathogenesis and leads to differences 
in the persistence, which are the limitations of the bleomycin induced pulmonary fibrosis 
model. Moreover this model makes it difficult to discriminate between anti-inflammatory or 
anti-fibrotic effects (Moeller, Rodriguez-Lecompte et al. 2006). In this study we slightly 
modified this disease model. Instead of an intratracheally or intravenous application, we 
administered BLM intranasally in anesthetized mice. As proof of feasibility using Evans 
Blue showed that this application route only gave rise to pulmonary distribution of the fluid 
and that the gastrointestinal tract was unaffected. Moreover an equal collagen deposition 
was achieved by an intranasal BLM instillation compared with an injection into the 
trachea. These results reveal that this is a feasible and proper method, with the advantage 
to avoid surgical intervention and an increased survival during the application.  
As mentioned before we wanted to characterize the role of innate immunity in 
pulmonary fibrosis, in this context we intended to target macrophages. Therefore we used 
conditional PTEN and Arginase 1 knockout mice with the genetic background of the 
Cre/lox system. The cre (cyclization recombination) gene of the bacteriophage P1 
encodes for the site-specific DNA recombinase Cre. Cre recognizes the 34 bp long loxP 
(locus of X-over of P1) sites and removes DNA fragments between two directly repeated 
loxP sites. The excised DNA fragment forms a covalently closed circle. A common method 
to induce gene ablation only in macrophages is the administration of Cre expression 
under the regulation of the promoter of lysozym M, a rather specific protein for 
macrophages, and other myeloid cells. In mice two isotypes are known the LysM and 
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LysP, which are found in myeloid cells and in Paneth cells of the gut, respectively. 
Although LysM was recognized as a major constitutive secreted protein of inflammatory 
macrophages, it is also expressed and stored by granulocytes (Gordon 2003). Moreover 
the expression of LysM was detected in non-hematopoietic cells, the alveolar type II cells 
and the precursor cells of the interventricular septum of the heart (Stadtfeld, Ye et al. 
2007). In contrast tissue macrophages and most other cell types, such as T- and B 
lymphocytes, lack LysM expression (Hume 2010).  
A disadvantage of the Cre/lox system is that random monoallelic inactivation can 
lead to variation in the target gene down regulation among individual mice and even bone 
marrow derived macrophage populations (Faust, Varas et al. 2000). Apart from that the 
Cre/lox system provides a great possibility to generate animals with a partial knockout, 
thus avoiding lethality due to a complete knockout in all cell types. An additional benefit of 
the Cre/lox system is that properties of gene products of specific cell types can be 
determined. In our trial we are interested in the role of myeloid PTEN in pulmonary 
fibrosis. A loss of function mutation of pten leads to embryonic death after embryonic day 
(E) 7.5 (Di Cristofano, Pesce et al. 1998). Consequently a conditional knockout provides 
the option to create PTEN deficiency, without developmental failure (Hume 2010). 
First we wanted to figure out if myeloid PTEN has an influence on pulmonary 
fibrosis. In that regard our primary aim was to characterize differences in the development 
of fibrosis between wild-type and myeloid PTEN deficient mice. The outcome of the BLM 
induced pulmonary fibrosis indicated that the ablated myeloid PTEN expression triggered 
a more severe outcome of fibrosis. Observations of increased loss of body weight, 
elevated hydroxyproline values in the lung and histological sections were the basis for this 
hypothesis. Collagen deposition displayed by Sirius Red staining and infiltration of 
immune cells demonstrated by H&E staining point out that the loss of PTEN in myeloid 
cells exacerbates pulmonary fibrosis. This leads to the suggestion that hyperactivity of 
PI3K, due to the lack of its inhibitor PTEN, may mediate effector mechanisms that could 
promote fibrosis.  
To elucidate the possible effector functions of the PI3K various fibrosis and 
inflammation related cytokines were determined after BLM treatment. Surprisingly we 
found pro-inflammatory cytokines, such as IL-17, IL-6, MIP2 and KC elevated in myeloid 
PTEN deficient mice. This may demonstrate that BLM induced pulmonary fibrosis is 
elicited by different mechanism than S. pneumoniae or activation of macrophages by LPS. 
The important cell membrane molecule of gram negative bacterial LPS is known to trigger 
the immune response via TLR4, while gram positive bacteria S. pneumoniae induce the 
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inflammatory response mainly via the binding of lipoteichoic acid to TLR2. Both TLRs 
mediate a decrease in pro-inflammatory cytokines via the inhibition of GSK-3β and the 
consequently diminished activation of CREB (Martin, Rehani et al. 2005). One attempt to 
explain this phenomenon could be that other signaling pathways are strongly induced and 
lead to the augmented pro-inflammatory cytokines and dominate the anti-inflammatory 
effects of PTEN deficiency during pulmonary fibrosis. Another possibility could be that, in 
the early immune response pro-inflammatory cytokines are still decreased in conditional 
myeloid PTEN knockout mice compared to wild-types, but maybe persistent stimuli of the 
pulmonary disease trigger cytokine expression through different downstream pathways.  
Inflammation often triggers and accompanies fibrosis. The great number of various 
cytokines, chemokines and immune cells makes it difficult to identify the precise role of 
inflammation. For example on the one hand overexpression of TNF can lead to fibrosis. 
Based on this knowledge there were many trials to use antagonists against TNF as 
therapeutic invention. Unlike the expectations this attempt failed, inhibition of TNF via its 
antagonists directed an even severer outcome of fibrosis. This effect is traced to the 
finding that TNF can slow down collagen synthesis and thereby attenuate the level of the 
disease (Wynn 2011).  
Wynn proposes that a strong inflammatory response at the beginning and a 
diminished inflammation at later time points contribute to fibrotic progression. Our 
observation was that mice lacking PTEN in the myeloid cell lineage demonstrated more 
inflammation and fibrosis at day 7 after BLM application, hence we assume that the time 
point is an important factor and crucial for the development of the disease. The different 
stages of fibrosis offer possibilities for explanation. Based on the idea that immune cells 
increase the levels of IL-13 and TGF-β at the beginning of the medical condition, they 
promote pathogenesis. In contrast due to the character of inflammatory cells, they can 
down regulate fibrosis at later stages, by the clearance of cell debris and controlling of cell 
proliferation (Wilson and Wynn 2009). In contrast immune cells could also produce pro-
fibrotic cytokines at later stages of fibrosis and therefore contribute to the disease. The 
expression pattern of pro- or anti-inflammatory cytokines seems to change during disease 
progression and should be addressed in further experiments.  
Another possibility could be that PI3K activity in immune cells is not mediated by 
TLRs but by cytokines and therefore comprises different effects. In fibrosis IL-4 and IL-13 
are augmented (Wynn 2004), for that reason we analyzed in vitro if these cytokines are 
able to initialize PI3K signaling. By means of western blot analysis we could show that the 
downstream kinases Akt and GSK-3β got phosphorylated after IL-4 and IL-13 stimulation, 
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which pointed out that they influence PI3K activity. This effect was strongly increased in 
myeloid PTEN deficient macrophages. Possibly these cytokines stimulate the PI3K to 
induce cell survival in macrophages via the inhibition of caspase 9 and Bcl-2-associated 
death promoter (BAD) during tissue remodeling (Marone, Cmiljanovic et al. 2008). In this 
context PI3K maybe thwart macrophage clearance. To elucidate this issue macrophage 
numbers of wild-type and PTEN deficient mice have to be compared for example via flow 
cytometry or H&E staining of cytospins of the cells of the bronchoalveolar lavage.  
Furthermore IL-4 and IL-13 are important cytokines for the alternatively activation of 
macrophages, in contrast to INF-γ, which endorses classical activation. These different 
stimuli of macrophage activation trigger diverse phenotypes. In consequence of the 
observation that IL-4 and IL-13 raise PI3K activity, we wanted to assay if the M2 
phenotype is altered by elevated PI3K signaling. In this perspective we investigated, if 
myeloid PTEN deficient macrophages exhibit a different phenotype due to IL-4 or IL-13 
stimulation in vitro. Markers of M2 polarization were checked on mRNA level. The 
experiment made obvious that there were differences in the M2 expression pattern. The 
alternative activation marker YM1 was significantly decreased in the absent of PTEN, 
similar the M2 chemokines CCL17 and CCL22 were diminished after stimulation with the 
type 2 cytokines, while baseline levels are constant. In contrast FIZZ was increased, 
especially due to IL-4 stimulation, although untreated macrophages lacking PTEN had 
significantly reduced amount of this M2 marker. To further elucidate their phenotype we 
analyzed Arginase 1 and its counter actor iNOS, which are indicators for a M2 and M1 
functional phenotype, respectively, and we found out that they were differentially 
expressed. In PTEN deficient macrophages Arginase 1 was increased and iNOS 
decreased. Moreover we could confirm this data on protein level. Western blot analysis 
showed in addition that PTEN deficient alveolar macrophages have increased levels of 
Arginase 1 in response to IL-4 and IL-13 stimulation. These dissimilarities of the M2 
expression profile showed that the PI3K/PTEN axis influences the M2 polarization and 
that the absence of PTEN promotes a M2 like phenotype. Maybe the PI3K can activate 
the transcription factor STAT6 or C/EBPβ (El Kasmi, Qualls et al. 2008) and thus induce 
Arginase 1. Perhaps in a similar way as IL-4 and IL-13 activate STAT6 and therefore lead 
to the activation of M2 genes, such as Arginase I (Welch, Escoubet-Lozach et al. 2002). 
Maybe reporter assays will help to clarify this question. 
IL-4 and IL-13 are famous for their action on macrophages to polarize them toward a 
M2 phenotype (Gordon 2003) and in addition they play an important role in the 
development of pulmonary fibrosis. Due to the finding of varieties in the expression 
pattern of macrophages after alternative activation, it could be possible that the release of 
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IL-4 and IL-13 during lung fibrosis has different effects in the myeloid PTEN deficient mice 
than in the wild-type mice. With this background it could be that the negative effects of IL-
4 and IL-13 on progression of the disease are even worse in conditional PTEN knockout 
mice. To identify more precisely if alteration in the M2 phenotype of macrophages could 
play a role during pulmonary fibrosis we examined the expression of Arginase 1 during the 
disease. 
Interestingly we found out that BLM induced the expression of Arginase 1 in wild-
type and myeloid PTEN deficient mice and similar to the in vitro studies the concentration 
was elevated in the conditional knockout mice. Arginase 1, which is a urea cycle enzyme, 
converts L-arginine into L-ornithine and urea; L-ornithine is further converted into L-proline 
and polyamines. L-proline is a very important compound of collagen and in this context 
Arginase 1 is implicated as a driver of collagen deposition and fibrosis (Wynn 2004). 
Augmented Arginase activity induces a depletion of L-arginine in the microenvironment, 
which leads to the failure of T-cells to express the ζ-chain of the TCR, and the lack of L-
ornithine impairs the cell proliferation and differentiation (Baniyash 2004). This effect could 
be the reason for the diminished number of T-cells in myeloid PTEN deficient mice during 
pulmonary fibrosis seen by flow cytometry. The reduced number of T-cells can either 
promote or inhibit fibrosis dependent on their differentiation towards TH2 or TH1 cells, 
respectively. To elucidate their cytokine expression profile ELISAs were performed 
indicating that INF-γ, IL-4 and L-17 were increased in myeloid PTEN deficient mice, 
leading to the suggestion that these cytokine differences may be driven by innate immune 
cells. To verify this idea intracellular staining of these cytokines and flow cytometry 
analysis would be helpful. 
Furthermore the increased Arginase 1 concentration could induce higher L-proline 
levels. After hydroxylation L-proline becomes hydroxyproline, which is a main component 
of collagen. In this context Arginase 1 may support collagen deposition by myofibroblasts 
and therefore the development of fibrosis. To find out if myeloid cells mediate the 
Arginase 1 expression during pulmonary fibrosis, we treated myeloid Arginase 1 deficient 
mice with bleomycin and investigated the Arginase 1 expression. We could demonstrate 
that myeloid Arginase 1 deficient mice had no or a strongly reduced Arginase 1 
expression post BLM instillation. The little Arginase 1 expression is probably due to the 
incomplete knockout of Arginase 1 or due to other unidentified Arginase 1 expressing 
cells, which contribute to the disease. This result shows that Arginase 1 in pulmonary 
fibrosis is mainly produced by myeloid cells, including an important role of these cells 
during the disease.  
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Mice, which lack Arginase 1 expression in myeloid cells exhibit a protective 
phenotype within the first two days, suggesting a pro-fibrotic role of Arginase 1. Due to the 
concentration of BLM (0.5 iu) we failed to examine additional differences between the two 
genotypes after day 5 post BLM application. Since we could not detect Arginase 1 in the 
bronchoalveolar lavage fluid three days after BLM treatment; maybe interstitial 
macrophages rather than alveolar macrophages trigger the protective phenotype on the 
first two days. Flow cytometry analysis indicated differences in the M2 phenotype of 
interstitial macrophages between myeloid PTEN deficient and wild-type mice differs, thus 
maybe interstitial macrophages effect fibrotic progression.  
 
An experiment with a lower dose of BLM (0.1 iu) did not show any differences in the 
cytokine levels between the myeloid Arginase 1 deficient mice and wild-types, except 
TNF-α and IL-4. This effect could be due to the possible protective downstream effect of 
Arginase 1 activity. The experiment will be repeated with an adequate concentration of 
BLM. Pesce and colleagues showed that Arginase 1 deficiency in myeloid cells lead to 
more severe schistosomias mediated liver fibrosis. They argued that Arginase 1 activity 
leads to a depletion of L-arginine, which is important for T helper cell proliferation and 
therefore down regulates their effector function. Additional they think that myeloid 
Arginase 1 competes with Arginase 1 of myofibroblasts for L-arginine and therefore 
reduce the collagen synthesis of myofibroblasts. Another proposed possibility was that 
mitochondrial Arginase 2 converts L-arginine instead of Arginase 1 and promotes L-
proline synthesis, because of its colocalization with L-ornithine decarboxylase (ODC) 
(Pesce, Ramalingam et al. 2009). Taking these results together Arginase 1 has a pro-
fibrotic as well as a protective character and that possibly the concentration is crucial for 
its effects. Moreover Arginase 1 can have contradictory effects on fibrosis dependent on 
the time point. Additionally the balance between Arginase 1 and iNOS may be important 
for efficient wound healing. Treatment of wild-type mice with recombinant Arginase 1 
during BLM induced fibrosis may facilitate the clarification of the amount of Arginase 1 
with beneficial characteristics.  
Many open questions still remain and have to be elucidated. The next main aim is 
the establishment of a cytokine profile that accompanies fibrosis, by measuring cytokines 
and chemokines at various time points. This will be helpful to establish possible 
expression differences between wild-types and conditional knockout mice and to figure 
out which consequences the lack of PTEN implicates and how it may manipulate the 
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development of fibrosis. Additional it is planned to re-stimulate T-lymphocytes of the lung 
with anti-CD3 / CD28 antibodies to amplify T-cell cytokines and to intensify differences. 
Moreover one important experiment will be to characterize the phenotype of myeloid 
Arginase 1 deficient mice after BLM administration. On that account it is planned to treat 
myeloid Arginase 1 knockout mice and littermate controls with BLM for three weeks and to 
measure the hydroxyproline levels of the lungs and figure out if there are differences in 
the collagen deposition depicted by histological staining.  
In order to identify how PI3K signaling may alter the M2 phenotype and the outcome 
of fibrosis, we want to characterize if this signaling pathway changes the expression of 
transcription factors. In this regard mRNA levels can be examined and then verified by 
western blotting.  
According to the clarifying of the effector mechanisms rescue experiments are 
scheduled. In this context myeloid PTEN deficient mice will be treated with the Arginase 1 
inhibitor N (omega)- hydroxyl- l- arginine (NOHA) and monitored if the phenotype can be 
recovered. In addition double knockout mice with a lack of PTEN and Arginase 1 in 
myeloid cells can be tested for fibrosis development. 
 
 94 
 
 
List of Figures 
95 
8. List of Figures 
Figure 1: Phosphoinositide 3-kinase pathway. Modified from (Gunzl and Schabbauer 2008) ......... 17 
Figure 2: L-arginine conversion by Arginase versus iNOS in murine myeloid cells (Munder 2009). 20 
Figure 3: Phenotypical characterization of M1 macrophages and its communication with Th1 cells 
and NK cells. Reactive nitrogen intermediates (RNI), reactive oxygen intermediates (ROI). 
(Biswas and Mantovani 2010) ................................................................................................... 22 
Figure 4: Phenotypical characterization of M2 macrophages and its communication with TH2 cells, 
basophils and innate lymphoid cells. (Biswas and Mantovani 2010) ........................................ 24 
Figure 5: Differentiation pathways of dendritic cells. (Kushwah and Hu 2011) ................................ 27 
Figure 6: Phases of wound healing response and their possible contribution to fibrosis. (Wynn 
2011) ......................................................................................................................................... 31 
Figure 8: Sirius red stained lung sections 21 d post bleomycin instillation. The left lung represents a 
healthy mouse, while in the middle and the right the lung originate from mice treated with 
bleomycin intranasally (i.n.) and intratracheally (i.t.), respectively. .......................................... 62 
Figure 9: Quantification of the area of collagen deposition. Different routes (intratracheally (i.t.) and 
intranasally (i.n.)) and different concentrations (0.05 iu and 0.15 iu) were tested. ................... 62 
Figure 10: Comparison of the cytokine levels between healthy mice and bleomycin treated mice. 
Whole lung tissue was homogenized and cytokines were measured by ELISA. Error bars 
show the standard deviations of the mean. (n.d…not determined) .......................................... 63 
Figure 11: Comparison of the cytokine levels between healthy mice and bleomycin treated mice. 
The cytokines of the bronchoalveolar lavage fluid were measured by ELISA. Error bars show 
the standard deviations of the mean. ........................................................................................ 64 
Figure 12: Wild-type and PTEN deficient alveolar macrophages were stimulated with LPS. The 
PI3K activity was examined by the phosphorylation of the two downstream kinases Akt and 
GSK-3β. Determination of actin was used as loading control. ................................................. 65 
Figure 14: Comparison of fibrotic markers between WT and myeloid PTEN KO mice. A) Body 
weight loss of mice after bleomycin administration. B) Hydroxyproline (OH-Proline) content in 
murine lungs 21 day post bleomycin treatment. Error bars show the standard deviations of the 
mean. ........................................................................................................................................ 67 
Figure 15: Histological specimen of murine lung tissue. The left column present the control lung 
treated with saline, the middle column demonstrates the lung of a wild-type mouse 21 day 
post bleomycin treatment and the right one covers the bleomycin treated lung of a myeloid 
PTEN knockout mouse. The two upper rows display the collagen deposition via Sirius Red 
staining. The third and fourth rows demonstrate the hematoxylin and eosin staining. Images of 
List of Figures 
96 
each row top-down are shown at 12.5, 40, 12.5 and 200 x magnification. Tissue was 
embedded in paraffin and 2 µm sections were prepared. ........................................................ 68 
Figure 16: Flow cytometric analysis of murine lung cell suspension 7 days post bleomycin 
treatment. Wild-type mice were compared with myeloid PTEN deficient mice. Each genotype 
is represented by two mice. Different markers were applied to identify macrophages, DCs, NK-
cells, B-cells, T-cells, Th cells, cytotoxic T-cells and TREG-cells. .............................................. 70 
Figure 17: IL-6 and KC expression 7 days post bleomycin treatment. RNA was isolated from lungs 
of myeloid PTEN knockout mice and wild-type littermates. Error bars show the standard 
deviations of the mean. ............................................................................................................. 71 
Figure 18: Wild-type and myeloid PTEN deficient mice were treated with bleomycin for 7 days and 
subsequently their lungs were homogenized and analyzed by ELISA. Error bars show the 
standard deviations of the mean. .............................................................................................. 72 
Figure 19: Wild-type and myeloid PTEN deficient mice were treated with bleomycin, at day 7 the 
bronchoalveolar lavage fluid was collected and analyzed by ELISA. Error bars show the 
standard deviations of the mean. (n.d…not determined) ......................................................... 73 
Figure 20: Western Blot analysis of wild-type and myeloid deficient alveolar macrophages after 10, 
30 or 60 minutes stimulation with IL-4 and IL-13. As target the phosphorylation state of the 
PI3K downstream kinases Akt and GSK-3β were investigated. Actin was used as loading 
control. ...................................................................................................................................... 74 
Figure 21: Flow cytometry analysis of murine lungs for M1 and M2 markers. Interstitial, alveolar 
macrophages and dendritic cells were examined. Gating strategy: excluding of the dead cells 
via the viability dye, elimination of the doublets according to the forward and side scatters, 
taking of the CD45+ cells and separating them according to CD11b and CD11c expression . 76 
Figure 22: mRNA levels of M2 markers of WT and PTEN deficient alveolar macrophages after 
stimulation with IL-4, IL-13 or heat killed S. pneumonia. The levels are expressed as fold 
change of the untreated control. Error bars show the standard deviations of the mean. Not 
determined (n.d.). ...................................................................................................................... 79 
Figure 23: Expression of iNOS of alveolar macrophages in response to LPS or heat killed S. 
pneumonia. Wild-type mice were compared with myeloid PTEN deficient mice. The levels are 
expressed as fold change of the untreated control. Error bars show the standard deviations of 
the mean. .................................................................................................................................. 80 
Figure 24: Expression of Arginase 1 in wild-type and PTEN deficient alveolar macrophages after 
stimulation with IL4/IL13 overnight in vitro. As loading control actin was applied. ................... 81 
Figure 25: Cytospin of the bronchoalveolar lavage fluid. One example of a macrophage and a 
neutrophil are indicated by a red and black arrow, respectively. .............................................. 81 
List of Figures 
97 
Figure 26: Western blot analysis of the expression of Arginase 1 and the release of albumin 7 days 
post bleomycin treatment. The expression was compared between myeloid PTEN deficient 
mice and their wild-type littermates. Actin was used as loading control. .................................. 82 
Figure 27: Illustration of the expression of Arginase 1 and release of albumin by western blot 
analysis 7 days after the bleomycin treatment. In this figure wild-types were compared with 
myeloid Arginase 1 deficient mice. The loading control was actin. .......................................... 83 
Figure 28: Percentage of body weight loss due to bleomycin treatment. The differences of the 
weights were shown from the days one, two and five post bleomycin instillation (from left to 
right) and wild-types and myeloid Arginase 1 deficient mice were compared. Error bars show 
the standard deviations of the mean. ........................................................................................ 84 
Figure 29: Cytokine levels of lung homogenates of myeloid Arginase 1 deficient mice and wild-type 
littermates 7 days post bleomycin treatment. Error bars show the standard deviations of the 
mean. ........................................................................................................................................ 85 
Figure 30: Cytokines of the bronchoalveolar lavage fluid of myeloid Arginase 1 deficient mice were 
compared with the cytokines of wild-type littermates. The mice were treated with bleomycin 
and after 7 days the lavage was performed. Error bars show the standard deviations of the 
mean. ........................................................................................................................................ 86 
List of Tables 
98 
9. List of Tables 
Table 1: Sequences of the PCR primers for genotyping .................................................................. 39 
Table 2: Description of the PCR programs ....................................................................................... 39 
Table 3: Hellabruner mixture ............................................................................................................. 41 
Table 4: Sequences of the used primers for Real time PCR. ........................................................... 51 
Table 5: Composition of the qPCR mastermix .................................................................................. 52 
Table 6: List of antibodies used for flow cytometry. .......................................................................... 58 
 
 
Curriculum Vitae 
99 
10. Curriculum Vitae 
Personal Information: 
Name: Julia Kral 
Date of Birth: 21.11.1988  
Place of Birth: 1180 Vienna 
Nationality: AUSTRIAN 
 
Education: 
2010 to 2012 Master studies “Genetic and Molecular Pathology” at the 
University of Vienna, Vienna I 
2007 to 2010 Bachelor studies “Molecular Biotechnology” at the University 
of Applied Sciences, Vienna III 
6th June 2007 Allgemeine Reifeprüfung (equivalent to the A levels in 
England) 
1999 to 2007 Realgymnasium Rosasgasse (similar to a secondary school) 
 
Work Experience:  
November 2011 to September 2012 Master Thesis 
“Investigation of the Role of PTEN and the Alternative Activation of 
Macrophages in Pulmonary Fibrosis“ 
Medical University of Vienna, Department of Physiology 
Research group: Protective signalling pathways in acute and chronic 
disease, Gernot Schabbauer, Ph.D. 
 
September and October 2011 Practical 
“The role of Lcn2 and IL-17 during pneumococcal pneumonia” 
Medical University of Vienna, Department of Medicine 1 
Research group: The innate immune response to bacterial infections, Silvia 
Knapp, M.D., Ph.D. 
 
 
Curriculum Vitae 
100 
January to May 2010  Bachelor Thesis 
“Evaluation of the capability of a panel of analytical methods to detect 
intentionally modified/degraded human coagulation factor IX” 
Octapharma Produktionsgesm.b.H. 
Katharina Pock, Ph.D. 
 
Literature 
101 
11. Literature 
Abramoff, M., P. Magalhaes, et al. (2004). "Image processing with ImageJ." Biophotonics 
International. 
Azambuja, E., J. F. Fleck, et al. (2005). "Bleomycin lung toxicity: who are the patients with 
increased risk?" Pulm Pharmacol Ther 18(5): 363-6. 
Bachman, M. A., V. L. Miller, et al. (2009). "Mucosal lipocalin 2 has pro-inflammatory and 
iron-sequestering effects in response to bacterial enterobactin." PLoS Pathog 
5(10): e1000622. 
Baniyash, M. (2004). "TCR zeta-chain downregulation: curtailing an excessive 
inflammatory immune response." Nat Rev Immunol 4(9): 675-87. 
Bataller, R. and D. A. Brenner (2005). "Liver fibrosis." J Clin Invest 115(2): 209-18. 
Beutler, B. (2004). "Innate immunity: an overview." Mol Immunol 40(12): 845-59. 
Biswas, S. K. and A. Mantovani (2010). "Macrophage plasticity and interaction with 
lymphocyte subsets: cancer as a paradigm." Nat Immunol 11(10): 889-96. 
Boutard, V., R. Havouis, et al. (1995). "Transforming growth factor-beta stimulates 
arginase activity in macrophages. Implications for the regulation of macrophage 
cytotoxicity." J Immunol 155(4): 2077-84. 
Bronte, V. and P. Zanovello (2005). "Regulation of immune responses by L-arginine 
metabolism." Nat Rev Immunol 5(8): 641-54. 
Cantley, L. C. (2002). "The phosphoinositide 3-kinase pathway." Science 296(5573): 
1655-7. 
Chaplin, D. D. (2003). "1. Overview of the immune response." J Allergy Clin Immunol 
111(2 Suppl): S442-59. 
Deshmane, S. L., S. Kremlev, et al. (2009). "Monocyte chemoattractant protein-1 (MCP-
1): an overview." J Interferon Cytokine Res 29(6): 313-26. 
Desjardins, M., J. E. Celis, et al. (1994). "Molecular characterization of phagosomes." J 
Biol Chem 269(51): 32194-200. 
Di Cristofano, A., B. Pesce, et al. (1998). "Pten is essential for embryonic development 
and tumour suppression." Nat Genet 19(4): 348-55. 
Domin, J. and M. D. Waterfield (1997). "Using structure to define the function of 
phosphoinositide 3-kinase family members." FEBS Lett 410(1): 91-5. 
Literature 
102 
El Kasmi, K. C., J. E. Qualls, et al. (2008). "Toll-like receptor-induced arginase 1 in 
macrophages thwarts effective immunity against intracellular pathogens." Nat 
Immunol 9(12): 1399-406. 
Faust, N., F. Varas, et al. (2000). "Insertion of enhanced green fluorescent protein into the 
lysozyme gene creates mice with green fluorescent granulocytes and 
macrophages." Blood 96(2): 719-26. 
Fruman, D. A. and L. C. Cantley (2002). "Phosphoinositide 3-kinase in immunological 
systems." Semin Immunol 14(1): 7-18. 
Fruman, D. A., F. Mauvais-Jarvis, et al. (2000). "Hypoglycaemia, liver necrosis and 
perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 
alpha." Nat Genet 26(3): 379-82. 
Galli, S. J., N. Borregaard, et al. (2011). "Phenotypic and functional plasticity of cells of 
innate immunity: macrophages, mast cells and neutrophils." Nat Immunol 12(11): 
1035-44. 
Gericke, A., M. Munson, et al. (2006). "Regulation of the PTEN phosphatase." Gene 374: 
1-9. 
Gordon, S. (2003). "Alternative activation of macrophages." Nat Rev Immunol 3(1): 23-35. 
Gordon, S. and F. O. Martinez (2010). "Alternative activation of macrophages: mechanism 
and functions." Immunity 32(5): 593-604. 
Gunzl, P. and G. Schabbauer (2008). "Recent advances in the genetic analysis of PTEN 
and PI3K innate immune properties." Immunobiology 213(9-10): 759-65. 
Harwood, N. E. and F. D. Batista (2008). "New insights into the early molecular events 
underlying B cell activation." Immunity 28(5): 609-19. 
Hay, J., S. Shahzeidi, et al. (1991). "Mechanisms of bleomycin-induced lung damage." 
Arch Toxicol 65(2): 81-94. 
Hodge, M. R., H. J. Chun, et al. (1996). "NF-AT-Driven interleukin-4 transcription 
potentiated by NIP45." Science 274(5294): 1903-5. 
Huaux, F., T. Liu, et al. (2003). "Dual roles of IL-4 in lung injury and fibrosis." J Immunol 
170(4): 2083-92. 
Hume, D. A. (2010). "Applications of myeloid-specific promoters in transgenic mice 
support in vivo imaging and functional genomics but do not support the concept of 
Literature 
103 
distinct macrophage and dendritic cell lineages or roles in immunity." J Leukoc Biol 
89(4): 525-38. 
Kim, H. S., H. Go, et al. (2011). "TLR2-mediated production of IL-27 and chemokines by 
respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in 
mice." J Immunol 187(8): 4007-17. 
Kim, J. I., I. C. Ho, et al. (1999). "The transcription factor c-Maf controls the production of 
interleukin-4 but not other Th2 cytokines." Immunity 10(6): 745-51. 
Krishnamoorthy, S. and K. V. Honn (2006). "Inflammation and disease progression." 
Cancer Metastasis Rev 25(3): 481-91. 
Kushwah, R. and J. Hu (2011). "Complexity of dendritic cell subsets and their function in 
the host immune system." Immunology 133(4): 409-19. 
Laird, M. H., S. H. Rhee, et al. (2009). "TLR4/MyD88/PI3K interactions regulate TLR4 
signaling." J Leukoc Biol 85(6): 966-77. 
Lieber, C. S. (1999). "Prevention and treatment of liver fibrosis based on pathogenesis." 
Alcohol Clin Exp Res 23(5): 944-9. 
Marone, R., V. Cmiljanovic, et al. (2008). "Targeting phosphoinositide 3-kinase: moving 
towards therapy." Biochim Biophys Acta 1784(1): 159-85. 
Martin, M., K. Rehani, et al. (2005). "Toll-like receptor-mediated cytokine production is 
differentially regulated by glycogen synthase kinase 3." Nat Immunol 6(8): 777-84. 
McInnes, A. and D. M. Rennick (1988). "Interleukin 4 induces cultured 
monocytes/macrophages to form giant multinucleated cells." J Exp Med 167(2): 
598-611. 
Medzhitov, R. (2007). "Recognition of microorganisms and activation of the immune 
response." Nature 449(7164): 819-26. 
Mehendale, H. M. (2005). "Tissue repair: an important determinant of final outcome of 
toxicant-induced injury." Toxicol Pathol 33(1): 41-51. 
Miller, J. C., B. D. Brown, et al. (2012). "Deciphering the transcriptional network of the 
dendritic cell lineage." Nat Immunol 13(9): 888-899. 
Moeller, A., J. C. Rodriguez-Lecompte, et al. (2006). "Models of pulmonary fibrosis." Drug 
Discovery Today: Disease Models 3(3): 243-2-49. 
Moore, B. B. and C. M. Hogaboam (2008). "Murine models of pulmonary fibrosis." Am J 
Physiol Lung Cell Mol Physiol 294(2): L152-60. 
Literature 
104 
Munder, M. (2009). "Arginase: an emerging key player in the mammalian immune 
system." Br J Pharmacol 158(3): 638-51. 
Munder, M., K. Eichmann, et al. (1999). "Th1/Th2-regulated expression of arginase 
isoforms in murine macrophages and dendritic cells." J Immunol 163(7): 3771-7. 
Munder, M., F. Mollinedo, et al. (2005). "Arginase I is constitutively expressed in human 
granulocytes and participates in fungicidal activity." Blood 105(6): 2549-56. 
Nair, M. G., Y. Du, et al. (2009). "Alternatively activated macrophage-derived RELM-
{alpha} is a negative regulator of type 2 inflammation in the lung." J Exp Med 
206(4): 937-52. 
Okada, T., L. Sakuma, et al. (1994). "Blockage of chemotactic peptide-induced stimulation 
of neutrophils by wortmannin as a result of selective inhibition of 
phosphatidylinositol 3-kinase." J Biol Chem 269(5): 3563-7. 
Pesce, J. T., T. R. Ramalingam, et al. (2009). "Arginase-1-expressing macrophages 
suppress Th2 cytokine-driven inflammation and fibrosis." PLoS Pathog 5(4): 
e1000371. 
Peyssonnaux, C., V. Datta, et al. (2005). "HIF-1alpha expression regulates the 
bactericidal capacity of phagocytes." J Clin Invest 115(7): 1806-15. 
Ratledge, C. and L. G. Dover (2000). "Iron metabolism in pathogenic bacteria." Annu Rev 
Microbiol 54: 881-941. 
Reese, T. A., H. E. Liang, et al. (2007). "Chitin induces accumulation in tissue of innate 
immune cells associated with allergy." Nature 447(7140): 92-6. 
Schabbauer, G., U. Matt, et al. (2010). "Myeloid PTEN promotes inflammation but impairs 
bactericidal activities during murine pneumococcal pneumonia." J Immunol 185(1): 
468-76. 
Schimanski, L. M., H. Drakesmith, et al. (2005). "In vitro functional analysis of human 
ferroportin (FPN) and hemochromatosis-associated FPN mutations." Blood 
105(10): 4096-102. 
Schluns, K. S. and L. Lefrancois (2003). "Cytokine control of memory T-cell development 
and survival." Nat Rev Immunol 3(4): 269-79. 
Sheppard, D. (2008). "The role of integrins in pulmonary fibrosis." European Respiratory 
Review 17(109): 157-162. 
Literature 
105 
Shmagel, K. V. and V. A. Chereshnev (2009). "Molecular bases of immune complex 
pathology." Biochemistry (Mosc) 74(5): 469-79. 
Sica, A. and A. Mantovani (2012). "Macrophage plasticity and polarization: in vivo veritas." 
J Clin Invest 122(3): 787-95. 
Stadtfeld, M., M. Ye, et al. (2007). "Identification of interventricular septum precursor cells 
in the mouse embryo." Dev Biol 302(1): 195-207. 
Suzuki, A., M. T. Yamaguchi, et al. (2001). "T cell-specific loss of Pten leads to defects in 
central and peripheral tolerance." Immunity 14(5): 523-34. 
Szabo, S. J., S. T. Kim, et al. (2000). "A novel transcription factor, T-bet, directs Th1 
lineage commitment." Cell 100(6): 655-69. 
Thannickal, V. J., G. B. Toews, et al. (2004). "Mechanisms of pulmonary fibrosis." Annu 
Rev Med 55: 395-417. 
Vanhaesebroeck, B., S. J. Leevers, et al. (2001). "Synthesis and function of 3-
phosphorylated inositol lipids." Annu Rev Biochem 70: 535-602. 
Welch, J. S., L. Escoubet-Lozach, et al. (2002). "TH2 cytokines and allergic challenge 
induce Ym1 expression in macrophages by a STAT6-dependent mechanism." J 
Biol Chem 277(45): 42821-9. 
Wilson, M. S., S. K. Madala, et al. (2010). "Bleomycin and IL-1beta-mediated pulmonary 
fibrosis is IL-17A dependent." J Exp Med 207(3): 535-52. 
Wilson, M. S. and T. A. Wynn (2009). "Pulmonary fibrosis: pathogenesis, etiology and 
regulation." Mucosal Immunol 2(2): 103-21. 
Wong, B. R., D. Besser, et al. (1999). "TRANCE, a TNF family member, activates Akt/PKB 
through a signaling complex involving TRAF6 and c-Src." Mol Cell 4(6): 1041-9. 
Wynn, T. A. (2004). "Fibrotic disease and the T(H)1/T(H)2 paradigm." Nat Rev Immunol 
4(8): 583-94. 
Wynn, T. A. (2008). "Cellular and molecular mechanisms of fibrosis." J Pathol 214(2): 
199-210. 
Wynn, T. A. (2011). "Integrating mechanisms of pulmonary fibrosis." J Exp Med 208(7): 
1339-50. 
Wynn, T. A. and T. R. Ramalingam (2012). "Mechanisms of fibrosis: therapeutic 
translation for fibrotic disease." Nat Med 18(7): 1028-40. 
Literature 
106 
Yang, H. Z., B. Cui, et al. (2009). "Targeting TLR2 attenuates pulmonary inflammation and 
fibrosis by reversion of suppressive immune microenvironment." J Immunol 182(1): 
692-702. 
Zhang, D. H., L. Cohn, et al. (1997). "Transcription factor GATA-3 is differentially 
expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the 
interleukin-5 gene." J Biol Chem 272(34): 21597-603. 
Zhu, J. and W. E. Paul (2010). "Heterogeneity and plasticity of T helper cells." Cell Res 
20(1): 4-12. 
 
 
